



US 20030119058A1

(19) **United States**

(12) **Patent Application Publication**  
**Qvist et al.**

(10) **Pub. No.: US 2003/0119058 A1**

(43) **Pub. Date: Jun. 26, 2003**

(54) **METHOD OF ASSAYING TYPE III COLLAGEN DEGRADATION**

**Publication Classification**

(75) Inventors: **Per Qvist**, Klampenborg (DK); **Martin Bonde**, Lyngby (DK)

(51) **Int. Cl.<sup>7</sup>** ..... **G01N 33/53**; C07K 14/78; G01N 33/537; G01N 33/543; C07K 2/00; C07K 4/00; C07K 5/00; C07K 7/00; C07K 14/00; C07K 16/00; C07K 17/00; A61K 38/00; A61K 38/04; C07K 1/00; C09H 1/00; A61K 38/17; G01N 33/545

Correspondence Address:  
**PENNIE & EDMONDS LLP**  
1667 K STREET NW  
SUITE 1000  
WASHINGTON, DC 20006

(52) **U.S. Cl.** ..... **435/7.1**; 530/356; 435/7.92; 435/7.93; 435/975; 436/518; 436/531; 530/328; 530/300

(73) Assignee: **Osteometer A/S**

(57) **ABSTRACT**


(21) Appl. No.: **10/058,124**

A method of assaying collagen fragments in body fluids, including bringing a sample of body fluid in contact with at least one immunological binding partner for the collagen fragments, said binding partner being immunoreactive with synthetic peptides, the sequences of which are essentially derived from collagen and containing potential sites for cross-linking. The immunological binding partners are incorporated, either as whole antibodies or as immunologically active fragments thereof, in an assay for quantitative determination of collagen fragments in the sample. In addition to being contacted with the immunological binding partner(s), the sample may be brought into direct contact with the corresponding synthetic peptide. The invention further comprises a test kit and specific means for carrying out the method. The structure of specific peptides is also described.

(22) Filed: **Jan. 29, 2002**

**Related U.S. Application Data**

(60) Division of application No. 09/570,573, filed on May 12, 2000, now Pat. No. 6,342,361, which is a division of application No. 08/963,825, filed on Nov. 4, 1997, now Pat. No. 6,110,689, which is a continuation of application No. 08/187,319, filed on Jan. 21, 1994, now abandoned.






FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6

FIG. 7



## METHOD OF ASSAYING TYPE III COLLAGEN DEGRADATION

[0001] The present invention relates to a method of determining collagen fragments in body fluids. The invention further relates to means, including synthetic peptides, monoclonal and polyclonal antibodies and cell lines, for use in carrying out the method of the invention. Still further, the invention relates to the use of the above method to diagnose the presence of disorders associated with the metabolism of collagen, especially osteoporosis.

### BACKGROUND OF THE INVENTION

[0002] Collagens and Disorders of Collagen Metabolism

[0003] Osteoporosis is the most common bone disease in humans. Primary osteoporosis, accompanied by increased susceptibility to fractures, results from a progressive reduction in skeletal bone mass. It is estimated to affect 15-20 million individuals in the USA alone. Its basis is an age-dependent imbalance in bone remodeling, i.e., in the rates of formation and resorption of bone tissue.

[0004] In the USA about 1.2 million osteoporosis-related fractures occur in the elderly each year including about 538,000 compression fractures of the spine, about 227,000 hip fractures and a substantial number of early fractured peripheral bones. Between 12 and 20% of the hip fractures are fatal because they cause severe trauma and bleeding, and half of the surviving patients require nursing home care. Total costs from osteoporosis-related injuries now amount to at least \$10 billion annually in the USA (Riggs, *New England Journal of Medicine* 327:620-627 (1992)).

[0005] Osteoporosis is most common in postmenopausal women who, on average, lose 15% of their bone mass in the 10 years after menopause. This disease also occurs in men as they get older and in young amenorrhic women athletes. Despite the major, and growing, social and economic consequences of osteoporosis, the availability of reliable assays for measuring bone resorption rates in patients or in healthy subjects is very limited. Other disorders entailing (and correlated with) abnormalities in collagen metabolism include Paget's disease, Marfan's syndrome, osteogenesis imperfecta neoplastic growth in collagenous tissue, dwarfism, rheumatoid arthritis, osteoarthritis and vasculitis syndrome.

[0006] Three known classes of human collagen have been described to date. The Class I collagens, subdivided into types I, II, III, V, and XI, are known to form fibrils. Their full amino-acid sequence (to the extent they have been elucidated) are attached in Appendix A.

[0007] Collagen type I accounts for more than 90% of the organic matrix of bone. Therefore, in principle, it is possible to estimate the rate of bone resorption by monitoring the degradation of collagen type I. Likewise, a number of other disease states involving connective tissue can be monitored by determining the degradation of collagen. Examples are collagen type II degradation associated with rheumatoid arthritis and osteoarthritis and collagen type III degradation in vasculitis syndrome.

[0008] Amino acid sequences of human type III collagen, human pro 1(II) collagen, and the entire prepro 1(III) chain of human type III collagen and corresponding cDNA clones

have been investigated and determined by several groups of researchers; see Loil et al., *Nucleic Acids Research* 12:9383-9394 (1984); Sangiorgi et al., *Nucleic Acids Research* 13:2207-2225 (1985); Baldwin et al., *Biochem. J.* 262:521-528 (1989); and Ala-Kokko et al., *Biochem. J.* 260:509-516 (1989).

[0009] Type I, II, and III collagens are all formed in the organism as procollagen molecules, comprising N-terminal and C-terminal propeptide sequences, which are attached to the core collagen molecules. After removal of the propeptides, which occur naturally in vivo during collagen synthesis, the remaining core of the collagen molecules consists largely of a triple-helical domain having terminal telopeptide sequences which are non-triple-helical. These telopeptide sequences have an important function as sites of intermolecular cross-linking of collagen fibrils extracellularly. The alpha-helical region also includes crosslinkable sites. Peptides from this region are part of the present invention.

[0010] Intermolecular cross-links provide collagen fibrils with biomechanical stability. The formation of these cross-links is initiated by modification of lysine and hydroxylysine residues to the corresponding aldehydes. Several of these residues located on adjacent chains of collagen will spontaneously form different intermolecular cross-links. The exact position of the sites for cross-linking on collagen telopeptides and from the helical region has been previously described. See, for example, Kuhn, K., in *Immunochemistry of the Extracellular Matrix* 1:1-29, CRC Press, Inc., Boca Raton, Fla. (1982), Eyre, D. R., *Ann. Rev. Biochem.* 53:717-48 (1984) or U.S. Pat. No. 5,140,103). Furthermore, the amino acid sequences of some potential sites for cross-linking in type I, II, and III collagen are given in Table 1 below.

[0011] The fibrous proteins, collagen and elastin, are cross-linked by a unique mechanism based on aldehyde formation from lysine or hydroxylysine side chains. Four homologous loci of cross-linking are evident in molecules of type I, II and III collagens (for review see Kuhn, K., in *Immunochemistry of the Extracellular Matrix* 1:1-29 (1982)). Two are aldehyde sites, one in each telopeptide region. The other two sites are hydroxylysine symmetrically placed at about 90 residues from each end of the molecule. When collagen molecules pack into fibrils, these latter sites in the helical region align and react with telopeptide aldehydes in adjacent molecules. There is now strong evidence that 3-hydroxypyridinium residues are the mature cross-link coming from hydroxylysine-derived aldehydes. The mature cross-linking residues of the other pathway, i.e. from aldehyde formation of lysine residues, is, however, still unknown.

[0012] Prior Art Assays for Collagen Degradation

[0013] In the past, assays have been developed for monitoring degradation of collagen in vivo by measuring various biochemical markers, some of which have been degradation products of collagen. However, none of these methods are based upon the use of immunological binding partners in the form of antibodies which are immunoreactive with synthetic peptides having a sequence essentially derived from collagen fragments having crosslinkable sites.

[0014] For example, hydroxyproline, an amino acid largely restricted to collagen, and the principal structural

protein in bone and all other connective tissues, is excreted in urine. Its excretion rate is known to be increased in certain conditions, notably Paget's disease, a metabolic bone disorder in which bone turnover is greatly increased, as discussed further below.

[0015] For this reason, urinary hydroxyproline has been used extensively as an amino acid marker for collagen degradation; Singer, F. R. et al., *Metabolic Bone Disease, Vol. II* (eds. Avioli, L. V., and Kane, S. M.), 489-575 (1978), Academic Press, New York.

[0016] U.S. Pat. No. 3,600,132 discloses a process for the determination of hydroxyproline in body fluids such as serum, urine, lumbar fluid and other intercellular fluids in order to monitor deviations in collagen metabolism. The patent states that hydroxyproline correlates with increased collagen anabolism or catabolism associated with pathological conditions such as Paget's disease, Marfan's syndrome, osteogenesis imperfecta, neoplastic growth in collagen tissues and in various forms of dwarfism.

[0017] Bone resorption associated with Paget's disease has also been monitored by measuring small peptides containing hydroxyproline, which are excreted in the urine following degradation of bone collagen; Russell et al., *Metab. Bone Dis. and Rel. Res.* 4 and 5:255-262 (1981), and Singer, F. R., et al., supra.

[0018] In the case of Paget's disease, the increased urinary hydroxyproline probably comes largely from bone degradation; hydroxyproline, however, generally cannot be used as a specific index for bone degradation. Much of the hydroxyproline in urine may come from new collagen synthesis (considerable amounts of the newly made protein are degraded and excreted without ever becoming incorporated into tissue fabric), and from turnover of certain blood proteins as well as other proteins that contain hydroxyproline.

[0019] Furthermore, about 80% of the free hydroxyproline derived from protein degradation is metabolized in the liver and never appears in the urine. Kivirikko, K. I., *Int. Rev. Connect. Tissue Res.* 5:93 (1970), and Weiss, P. H. and Klein, L., *J. Clin. Invest.* 48:1 (1969). Hydroxyproline is a good marker for osteoporosis, but it is troublesome to handle. It is specific for collagen in bones.

[0020] Hydroxylysine and its glycoside derivatives, both peculiar to collagenous proteins, have been considered to be more accurate than hydroxyproline as markers of collagen degradation. However, for the same reasons described above for hydroxyproline, hydroxylysine and its glycosides are probably equally non-specific markers of bone resorption; Krane, S. M. and Simon, L. S. *Develop. Biochem.* 22:185 (1981).

[0021] Other researchers have measured the cross-linking compound 3-hydroxypyridinium in urine as an index of collagen degradation in joint diseases. See, for background and as examples, Wu and Eyre, *Biochemistry* 23:1850 (1984); Black et al., *Annals of the Rheumatic Diseases* 48:641-644 (1989); Robins et al.; *Annals of the Rheumatic Diseases* 45:969-973 (1986); and Seibel et al., *The Journal of Dermatology* 16:964 (1989). In contrast to the present invention, these prior researchers have hydrolyzed peptides from body fluids and then looked for the presence of individual 3-hydroxypyridinium residues.

[0022] Assays for determination of the degradation of type I, II, and III collagen are disclosed in U.S. Pat. Nos. 4,973,666 and 5,140,103. However, both these patents are restricted to collagen fragments containing the cross-linker 3-hydroxypyridinium, whereas the present invention does not rely on the presence or absence of this particular cross-linking structure. Furthermore, the above-mentioned assays require tedious and complicated purifications from urine of collagen fragments containing 3-hydroxypyridinium to be used for the production of antibodies and for antigens in the assays.

[0023] At present very few clinical data using the approach described in U.S. Pat. Nos. 4,973,666 and 5,140,103 are available. Particularly, no data concerning the correlation between the urinary concentration (as determined by methods described in the above-mentioned patents) of 3-hydroxypyridinium containing telopeptides of type I collagen and the actual bone loss (as determined by repeated measurements by bone densitometry) are published. The presence of 3-hydroxypyridinium containing telopeptides in urine requires the proper formation in bone tissue of this specific cross-linking structure at various times before the bone resorbing process. Very little information on these processes is available and the present invention seeks to circumvent this dependence of the correct formation of the cross-linking structure. Furthermore, preliminary data indicate that in one embodiment of the present invention a major fraction of the molecules reactive in the assay has a molecular weight of more than 4,000 daltons. On the contrary, only molecules with a molecular weight below 2,000 daltons are identified in urine with the monoclonal antibody used in the assay; Hanson et al., *Journal of Bone and Mineral Research* 7:1251-1258 (1992). This demonstrates that the method according to the present invention has a very different profile of reactivities, i.e. it detects very different molecules, compared to methods described in the two above-mentioned U.S. patents.

[0024] None of the above researchers have reported specifically assaying a crosslinkable collagen fragment that is naturally produced in vivo upon collagen degradation, as in the present invention.

[0025] GB patent application No. 2,205,643 reports that the degradation of type III collagen in the body can be quantitatively determined by measuring the concentration of an N-terminal telopeptide from type III collagen in a body fluid. This method does not relate to methods employing antibodies reactive with specific, low molecular weight sequences around crosslinkable structures. Instead, the method uses antibodies generated to N-terminal telopeptides released by bacterial collagenase degradation of type III collagen, said telopeptides being labelled and used in the assay.

[0026] There are a number of reports indicating that collagen degradation can be measured by quantitating certain procollagen peptides. Propeptides are distinguished from telopeptides and alpha-helical region of the collagen core by their location in the procollagen molecule and the timing of their cleavage in vivo; see U.S. Pat. Nos. 4,504,587; 4,312,853; Pierard et al., *Analytical Biochemistry* 141:127-136 (1984); Niemela, *Clin. Chem.* 31/8:1301-1304 (1985); and Rohde et al., *European Journal of Clinical Investigation* 9:451-459 (1979).

[0027] U.S. Pat. No. 4,778,768 relates to a method of determining changes occurring in articular cartilage involving quantifying proteoglycan monomers or antigenic fragments thereof in a synovial fluid sample. This US patent does not relate to detecting collagen fragments derived from degraded collagen.

[0028] Dodge, *J. Clin. Invest.* 83:647-661 (1981) discloses methods for analyzing type II collagen degradation utilizing a polyclonal antiserum that specifically reacts with unwound alpha-chains and cyanogen bromide-derived peptides of human and bovine type II collagens. Contrary to the present invention the degradation products of collagen were not detected in a body fluid, but histochemically by staining of cell cultures, i.e. by "in situ" detection. The main difference between Dodge and the present invention is that Dodge measures type II collagen degradation in situ. By "in situ" is meant a determination carried out in the cells or tissue in which the degradation takes place. There is quite a fundamental difference between this determination and a method based upon tracing a marker in vitro, e.g. in the urine.

[0029] None of these references specify the structures of particular telopeptide or alpha-helical degradation products that could be measured to determine the amount of degraded fibrillar collagen in vivo.

#### SUMMARY OF THE INVENTION

[0030] The present invention is based on the discovery of the presence of particular collagen fragments in body fluids of patients and normal human subjects. The collagen fragments are generated upon collagen degradation and are partly characterized by the presence of potential sites for cross-linking, e.g. by the presence of lysine or hydroxylysine (Kühn, K., *Immunochemistry of the Extracellular Matrix* 1:1-29 (1982)). It is believed that a fraction of the collagen fragments measured by the assays embodied in the present invention are normally covalently linked in vivo to other peptide fragments through different, unidentified or already identified cross-links.

[0031] The method of the present invention may be used for determination of the degradation of human collagen of type I, II, and III.

[0032] The present invention provides a method of assessing the degradation of collagen based on a determination of the presence and quantity of a particular class of collagen fragments produced in vivo upon collagen degradation; and a comparison of the detected collagen fragments to those of a predetermined standard developed by measuring the same class of collagen fragments in normal individuals, i.e. individuals not afflicted with a disorder affecting collagen metabolism, said individuals being sex- and age-matched with the subjects being tested.

[0033] The present invention uses antibodies immunoreactive with synthetic peptides without these cross-linking structures. Accordingly, it is believed that collagen fragments (corresponding to the synthetic peptides) with or without actual cross-links, but with crosslinkable sites, are measured in the assays embodied in the present invention.

[0034] In a preferred embodiment, the method is based on the competitive binding of collagen fragments in body fluids and of synthetic peptides essentially derived from collagen to immunological binding partners.

[0035] The present invention provides new and very simple procedures for the detection (qualitative and quantitative) of collagen fragments generated upon collagen degradation.

[0036] For purposes of the present invention, as disclosed and claimed herein, the following terms are as defined below:

[0037] "Antibody": A monoclonal or polyclonal antibody or immunoreactive fragment thereof (i.e. capable of binding the same antigenic determinant), including—but not limited to—Fab, Fab', and F(ab')<sub>2</sub> fragments.

[0038] "Crosslinkable sites": loci in collagen telopeptide or helix amino acid sequences containing lysine or hydroxylysine residues which can form cross-links with telopeptides or helical amino acid sequences of other collagen molecules in vivo.

[0039] "Crosslinkable peptides": peptides containing a fragment of the collagen sequence including at least one crosslinkable site.

[0040] Test kit: A combination of reagents and instructions for use in conducting an assay.

[0041] "Essentially derived" (about structures): Structures with similar antigenicity, i.e. with an ability, above the level of a non-related peptide, to inhibit the binding of any of the mentioned synthetic peptides to an antibody immunoreactive with said synthetic peptide.

[0042] It is contemplated that the method may also be used for assaying collagen fragments in animal body fluids, e.g. for determination of the collagen metabolism. It also can be used during clinical testing of new drugs to assess the impact of these drugs on collagen metabolism.

[0043] More specifically, the present invention relates to methods for assaying collagen fragments by the use of synthetic peptides corresponding to the above-mentioned sequences of collagen. Generally, these synthetic peptides will have fewer amino acid residues than the entire collagen molecule, often they will have fewer than 10 amino acids. Also, the synthetic peptides, corresponding to molecules present in body fluids, e.g. urine, will have potential sites for cross-linking, preferably lysine or hydroxylysine, incorporated in the structure.

[0044] The present invention comprises the determination of collagen fragments by the use of antibodies which are immunoreactive with the above-mentioned synthetic peptides, said peptides each having a sequence derived from collagen fragments having crosslinkable sites.

[0045] The invention also includes cell lines (e.g. hybridomas) that produce monoclonal antibodies immunoreactive with the above-mentioned synthetic peptides. The invention further includes monoclonal antibodies produced by the fused cell hybrids, and those antibodies (as well as binding fragments thereof, e.g. Fab) coupled to a detectable marker. Examples of detectable markers include, but are not limited to, enzymes, chromophores, fluorophores, coenzymes, enzyme inhibitors, chemiluminescent materials, paramagnetic metals, spin labels and radioisotopes.

[0046] The methods of the invention involve quantitating in a body fluid the concentration of particular collagen fragments derived from collagen degradation. In a represen-

tative assay, collagen fragments in the patient's body fluid and a synthetic peptide immobilized on a solid surface are contacted with an immunological binding partner which is immunoreactive with the synthetic peptide. Suitable body fluids are e.g. human urine, blood, serum, plasma and synovial fluid. It is contemplated that the method may also be used e.g. on saliva and sweat. The body fluid may be used as it is, or it may be purified prior to the contacting step. This purification step may be accomplished using a number of standard procedures, including, but not limited to, cartridge adsorption and elution, molecular sieve chromatography, dialysis, ion exchange, alumina chromatography, hydroxyapatite chromatography, and combinations thereof.

[0047] The present invention is based on the discovery of simple procedures for quantitation of collagen fragments in body fluids. In a representative procedure, synthetic peptides containing potential sites for cross-linking, are used for the raising of antibodies and subsequently incorporated in the assay for quantitation of collagen fragments generated in vivo by collagen degradation.

[0048] The invention also includes test kits useful for quantitating in a body fluid the amount of collagen fragment derived from the degradation of collagen. The kits comprise at least one immunological binding partner, e.g. a monoclonal or polyclonal antibody specific for a peptide derived from the degradation of collagen. If desired, the immunological binding partner of the test kit may be coupled to detectable markers such as the ones described above.

[0049] The invention is described in more detail below. Reference is made to the appended drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0050] FIGS. 1, 2 and 3 are typical standard curves for the  $\alpha 1(I)C1$  immunoassay (FIG. 1), the  $\alpha 1(I)N1$  immunoassay (FIG. 2) and the  $\alpha 2(I)N1$  immunoassay (FIG. 3) to be described in more detail in the examples;

[0051] FIG. 4 shows the correlation between total pyridinolin (HPLC) and the  $\alpha 1(I)C1$  immunoassay,

[0052] FIG. 5 shows the correlation between total pyridinolin (HPLC) and the  $\alpha 1(I)N1$  immunoassay,

[0053] FIG. 6 shows the individual values of the measurement of  $\alpha 1(I)C1$  peptide in urine samples from normal, age-matched women, and

[0054] FIG. 7 shows the individual values of the measurement of urine samples from women on a hormone replacement therapy and placebo in the  $\alpha 1(I)C1$  immunoassay.

#### DETAILED DESCRIPTION AND BEST MODE OF CARRYING OUT THE INVENTION

[0055] In a preferred embodiment of the method according to the invention, the assaying of type I, II and III collagen fragments in urine is performed by an inhibition ELISA (enzyme linked immunosorbent assay) by metering off a sample of urine and contacting the sample with a synthetic peptide having a sequence derived from collagen and with an antibody, which is immunoreactive with the synthetic peptide. The synthetic peptide is immobilized on a solid support. The antibody is raised against the synthetic peptide.

[0056] The combined reagents and sample are incubated, and a peroxidase-conjugated (revealing) antibody is added. After another incubation, a peroxidase substrate solution is added. Following short final incubation, the enzyme reaction is stopped, and the absorbance is measured at 450 nm and compared with a standard curve obtained with standard solutions by the same procedure.

[0057] Synthetic peptides are used for the preparation of standards. The concentration of synthetic peptide in a stock solution of the relevant synthetic peptide is determined by quantitative amino acid determination. A two-fold dilution of the stock solution is prepared and subsequently used for the construction of the standard curve in the inhibition ELISA.

#### [0058] Preparation of Synthetic Peptides

[0059] The preparation of synthetic peptides may be performed according to procedures well known in the art, e.g. by solid-phase peptide synthesis techniques commonly described as "Merrifield synthesis". Also classical solution phase techniques may be used. Sequences of interest include potential sites for cross-linking (see for example Kühn, K., in *Immunochemistry of the Extracellular Matrix* 1:1-29 (1982), Eyre, D. R., *Ann. Rev. Biochem.* 53:717-48 (1984), or U.S. Pat. No. 5,140,103). Examples of such peptides sequences are given in table 1 below.

[0060] Regarding the synthetic peptides, it is possible to omit (or add) one or more amino acid residues from (or to) the crosslinkable site sequences without substantial loss of the ability to (a) raise antibodies recognizing the corresponding native collagen fragment or (b) inhibit the bindings of such antibodies to the native fragment. It is possible to use longer collagen fragments and/or chimeric peptides to raise the antibodies and, in principle, it is not necessary to use the same peptide as the immunogen and the competitor in the assay.

Table 1

[0061] Examples of Amino acid sequences with potential sites for cross-linking in various types of collagen to be used as a basis for synthetic peptides according to the present invention

#### [0062] Collagen type I

[0063] Potential sites in telopeptides: N C

[0064]  $\alpha 1(I)N$ -term. Asp-Glu-Lys-Ser-Thr-Gly-Gly ( $\alpha 1(I)N1$ )

[0065]  $\alpha 1(I)C$ -term. Glu-Lys-Ala-His-Asp-Gly-Gly-Arg ( $\alpha 1(I)C1$ )

[0066]  $\alpha 2(I)N$ -term. Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly ( $\alpha 2(I)N1$ )

[0067]  $\alpha 2(I)C$ -term. no potential sites

#### [0068] Potential sites in helix:

[0069]  $\alpha 1(I)$  (near N) Gly-Met-Lys-Gly-His-Arg

[0070]  $\alpha 1(I)$  (near C) Gly-Ile-Lys-Gly-His-Arg

[0071]  $\alpha 2(I)$  (near N) Gly-Phe-Lys-Gly-Ile-Arg

[0072]  $\alpha 2(I)$  (near C) Gly-Leu-Pro-Gly-Leu-Lys-Gly-His-Asn

**[0073]** Collagen Type II**[0074]** Potential sites in telopeptides: N C**[0075]**  $\alpha 1$  (II) N-term. Pro-Gly-Pro-Lys-Gly-Glu Gly-Gln-Lys-Gly-Glu-Pro Gly-Asp-Ile-Lys-Asp-Ile-Val**[0076]**  $\alpha 1$  (II) C-term. Glu-Lys-Gly-Pro-Asp**[0077]** Potential sites in helix:**[0078]**  $\alpha 1$  (II) (near N) Gly-Val-Lys Pro-Gly-Val-Lys-Gly**[0079]** Collagen Type III**[0080]** Potential sites in telopeptides: N C**[0081]**  $\alpha 1$  (III) N-term. Asp-Val-Lys-Ser-Gly-Val**[0082]**  $\alpha 1$  (III) C-term. Glu-Lys-Ala-Gly-Gly-Phe-Ala**[0083]** Potential sites in helix:**[0084]**  $\alpha 1$  (III) (near N) Gly-Phe-Pro-Gly-Met-Lys-Gly-His-Arg**[0085]**  $\alpha 1$  (III) (near C) Gly-Ala-Ala-Gly-Ile-Lys-Gly-His-Arg**[0086]** Preparation of Antibodies

**[0087]** The methods for preparation of both monoclonal and polyclonal antibodies are well known in the art. For example, see Campbell, A. M., *Laboratory Techniques in Biochemistry and Molecular Biology*, Vol. 13 (1986). It is possible to produce antibodies to synthetic peptides by immunization. However, because of the relatively small molecular weight of these compounds it is preferred that the hapten be conjugated to a carrier molecule. Suitable carrier molecules include, but are not limited to, bovine serum albumin, thyroglobulin, ovalbumin, tetanus toxoid, and key-hole limpet hemocyanin. The preferred carrier is bovine serum albumin. To present the hapten in its most immunogenic form to the antibody producing cells of the immunized animal a number of alternative coupling protocols can be used. Suitable procedures include, but are not limited to, glutaraldehyde, carbodiimide, and periodate. Preferred binding agents are glutaraldehyde and carbodiimide.

**[0088]** The preparation of antibodies is carried out by conventional techniques including immunization with collagen fragments or synthetic peptides conjugated to a carrier. To improve the immunogenicity it is preferred that the immunogen be mixed with an adjuvant before injection. Examples of adjuvants include, but are not limited to, aluminum hydroxide, Freund's adjuvant, and immunostimulating complexes (ISCOMs). ISCOMs can be made according to the method described by Morein, B. et al., *Nature* 308:457-460 (1984).

**[0089]** Either monoclonal or polyclonal antibodies to the hapten carrier molecule can be produced. For the production of monoclonal antibodies it is preferred that mice are immunized. Spleen cells from the immunized mouse are harvested, homogenized, and thereafter fused with cancer cells in the presence of polyethylene glycol to produce a cell hybrid which produces monoclonal antibodies specific for peptide fragments derived from collagen. Suitable cancer cells include, but are not limited to, myeloma, hepatoma,

carcinoma, and sarcoma cells. Detailed descriptions of the production of monoclonal antibodies are provided in Goding, J. W., in *Monoclonal Antibodies: Principles and Practice*, (1986). A preferred preliminary screening protocol comprises the use of synthetic peptides conjugated to a carrier and coated onto the solid surface of a microtitre plate.

**[0090]** For the preparation of polyclonal antibodies, which are reactive with peptide fragments derived from collagen, different animal species can be immunized. Suitable species include, but are not limited to, chicken, rabbit and goat. Chicken and rabbit are preferred.

**[0091]** Antibody fragments are prepared by methods known in the art (see E. Ishikawa, *J. of Immunoassay* 3:209-327, 1983).

**[0092]** Conduct of Immunoassays

**[0093]** Accordingly, by utilization of an immunoassay with the antibodies prepared as above it is possible to assay a biological fluid sample without prior fractionation or hydrolysis. The specificity for the desired collagen in the biological fluid is supplied by the antibody in combination with the use of a synthetic peptide (against which the antibody was raised or in any event with which the antibody is immunochemically reactive) in the assay construction.

**[0094]** The immunoassays themselves are conducted using any procedure selected from the variety of standard assay protocols generally known in the art. As it is generally understood, the assay is constructed so as to rely on the interaction between the specific immunological binding partner and the desired analyte for specificity and to utilize some means to detect the complex formed by the analyte and the immunological binding partner. The immunological binding partner may be complexed to a solid support and used as a capture immunological binding partner for the analyte. This protocol may be run in a direct form, wherein the formation of analyte/immunological binding partner complex is detected, e.g. by a fluorescent, radioactive or enzymatic label, or it may be run in a competitive format wherein a labelled standard competes with the analyte for the immunological binding partner. The format may also be constructed as an agglutination assay or the complex may be precipitated by addition of a suitable precipitant to the reaction mixture. The specific design of the immunoassay protocol is open to a wide variety of choice, and the number of clinical assay devices and protocols available in the art is multitudinous. For a variety of such protocols, see U.S. Pat. No. 5,001,225.

**[0095]** The antibodies and revealing reagents for the conduct of an immunoassay using standard detection protocols, for example radioisotope labelling, fluorescent labelling or ELISA, either in a direct or competitive format, may conveniently be supplied as kits which include the necessary components and instructions for the assay. In one embodiment of the invention such a kit includes a microtiter plate coated with a relevant synthetic peptide, standard solutions for preparation of standard curve, a urine control for quality testing of the analytical run, rabbit antibodies reactive with the above-mentioned synthetic peptide, anti-rabbit immunoglobulins conjugated to peroxidase, a substrate solution, a stopping solution, a washing buffer and an instruction manual.

**[0096]** Since immunoassays can be constructed using antibodies and specific synthetic peptides, the ratios of the

corresponding collagen fragment sequences in an appropriate biological fluid can be determined as well as their individual levels and their total. Thus, the assay can be designed to include antibodies which will result in determination of several native peptide sequences or determination of a single peptide sequence, or any desired combination thereof.

**[0097]** In addition to the use of the herein specified peptides as indicators of bone resorption, bone metabolic balance is advantageously determined by the substantially simultaneous determination of a marker of the formation of bone in the same or other appropriate biological fluid from the same individual. "Substantially simultaneous" means the same day, preferably within 4 hours. For example such markers include osteocalcin (also known as bone GLA protein of BGP), procollagen type I, bone alkaline phosphatase and total alkaline phosphatase. Suitable methods for the determination of these markers can be found, for example, in Delmas, P. D., et al., *J. Bone Min. Res.* 1:333-337 (1986).

**[0098]** The assay of the present invention which provides an index to determination of the metabolic status of tissues, which generate collagen-derived peptides when degradation occurs, are useful in a variety of contexts. First, when considering the degradation of type I collagen, the assays are methods to assess an abnormal condition of a subject by indicating, for example, excessive bone resorption. This may show the presence of an osteoporotic condition or the metastatic progress of a malignancy. Other conditions characterized by excessive bone resorption include Paget's disease and hyperparathyroidism. Likewise, a number of other disease states involving connective tissue may be monitored by determination of the degradation of collagen. Examples are collagen type II degradation associated with rheumatoid arthritis and osteoarthritis and collagen type III degradation in vasculitis syndrome. Since the condition of the subject can be monitored continuously, application of these assays can also be used to monitor the progress of therapy administered to treat these or other conditions. Further, the assays can be used as a measure of toxicity, since the administration of toxic substances often results in tissue degradation.

**[0099]** Thus the assays may be applied in any situation wherein the metabolic condition of collagen tissues can be used as an index of the condition, treatment, or effect of substances directly administered to the subject or to which the subject is exposed in the environment.

**[0100]** The following examples are intended to illustrate, but not to limit the invention.

#### EXAMPLE 1

**[0101]** Immunoassays for Specific Peptide Sequences in Urine

**[0102]** Three peptides ( $\alpha 1(I)C1$ ,  $\alpha 1(I)N1$ , and  $\alpha 2(I)N1$ ) (see Table 1, p. 13) prepared by solid-phase techniques are used for the preparation of immunogens. For immunization, the peptides are covalently attached to bovine serum albumin using glutaraldehyde reagents and methods well known in the art. Both monoclonal and polyclonal antibodies are raised against the peptides. For production of monoclonal antibodies, Balb/c mice are immunized with peptide-BSA conjugates, and hybridoma cell lines are prepared using

standard techniques after fusion of cells from the spleen or lymph nodes with Ag8 myeloma cells. Polyclonal antibodies are raised in rabbits and chicken. Screening of both antisera and hybridoma cell media were performed by ELISA using microtiter plates coated with the appropriate peptide-gelatin conjugate prepared using carbodiimide reagents and methods well known in the art.

**[0103]** Assays for three of the peptide sequences ( $\alpha 1(I)C1$ ,  $\alpha 1(I)N1$ , and  $\alpha 2(I)N1$ ) in urine are performed by an inhibition ELISA as follows:

**[0104]** Urine samples (10 or 25 l) possibly containing collagen fragments or solutions containing 0.05-15 g peptide/ml as reference standards, respectively, are added to 75 l of immunological binding partners for the peptides diluted 1:5,000-1:20,000 in phosphate buffered saline containing 0.1% Tween-20 detergent (PBS-T) and including 0.1% (w/v) of BSA. Each sample is prepared in duplicate in flat-bottomed, 96-well microtiter plates previously coated with gelatin conjugate containing the appropriate peptide. After 60 minutes, the plates are washed with PBS-T (3 times) and the bound antibodies are detected by standard techniques with a horse radish peroxidase labelled antibody prepared against the species of the primary antibody. Peroxidase substrate is added and the color development is measured at 450 nm in an automated microtiter plate reader after stopping the enzyme reaction using 1 M H<sub>3</sub>PO<sub>4</sub>. Samples containing the analyte decrease the binding of primary antibody to the immunobilized peptide in the plate and thus have a reduced color concentration. The amount of analyte in the sample is quantified with reference to previously established curves from standards included on each plate computed using log-lin plots. **FIGS. 1, 2 and 3** show typical standard curves for the  $\alpha 1(I)C1$  immunoassay (**FIG. 1**),  $\alpha 1(I)N1$  immunoassay (**FIG. 2**), and  $\alpha 2(I)N1$  immunoassay (**FIG. 3**).

#### EXAMPLE 2

**[0105]** Correlation to Pyridinolin Determination on HPLC

**[0106]** On a number of unselected urine samples the concentration of total pyridinolin (HPLC method, see for example Uebelhart, D., *Bone and Mineral* 8:87-96 (1990)) was measured. Values obtained in this HPLC system were correlated to the values obtained in two immunoassays ( $\alpha 1(I)C1$  peptide and  $\alpha 1(I)N1$  peptide).

**[0107]** **FIG. 4** shows the correlation between total pyridinolin (HPLC) and  $\alpha 1(I)C1$  immunoassay (n=59). The correlation calculated by linear regression analysis is r=0.80.

**[0108]** **FIG. 5** shows the correlation between total pyridinolin (HPLC) and  $\alpha 1(I)N1$  immunoassay (n=36). The correlation calculated by linear regression analysis is r=0.95.

#### EXAMPLE 3

**[0109]** Clinical Results

**[0110]** The immunoassay procedure (using the  $\alpha 1(I)C1$  peptide) set forth in Example 1 was applied to urine samples from different individuals, and the amount of analyte was quantitated. The values obtained were related to the level of urinary creatinine in the urine sample as is commonly done for urine assays. The values obtained for normal, age-matched women (premenopausal and postmenopausal) are shown in Table 2.

TABLE 2

Measurement of $\alpha 1(I)C1$ peptide in urine samples from normal, age-matched women (premenopausal and postmenopausal)	
Group	$\alpha 1(T)C1$ peptide (g/mol creatinine)
Premenopausal (n = 104)	0.263 $\pm$ 0.143
Postmenopausal (n = 180)	0.426 $\pm$ 0.190

[0111] For individual values see FIG. 6.

[0112] The difference between the premenopausal and the post-menopausal values is highly significant (P<0.0001).

[0113] The z-score of a quantitative test procedure shows the ability of the procedure to distinguish between two populations. Table 3 below shows the z-score of the IC1 immunoassay and the state of the art measurement of pyridinolin on HPLC when applied to the same set of urine samples from normal, age-matched premenopausal (n=104) and postmenopausal women (n=180).

TABLE 3

Z-scores obtained for two different test procedures (total pyridinolin (HPLC) and $\alpha 1(I)C1$ immunoassay) when applied to urine samples from normal, age-matched women (premenopausal and postmenopausal)	
Test procedure	Z-score
$\alpha 1(I)C1$ immunoassay	1.14
Total pyridinolin (HPLC)	1.25

[0114] As can be seen from Table 3, the abilities of the two methods to distinguish between patient populations are approximately alike.

[0115] For an assay to be used as an index of bone resorption it is very important to be able to measure the impact of a hormone replacement therapy (HRT). Table 4 shows the results from the  $\alpha 1(I)C1$  immunoassay in such a study.

TABLE 4

Measurement of urine samples from women on a hormone replacement therapy and placebo in the $\alpha 1(I)C1$ immunoassay. Values given as percent of t = 0		
Group	$\alpha 1(I)C1$ peptide t = 0	( $\mu g/mol$ creatinine) t = 12 months
HRT (n = 92)	0.457 $\pm$ 0.176	0.176 $\pm$ 0.103
Placebo (n = 45)	0.459 $\pm$ 0.209	0.402 $\pm$ 0.187

[0116] For individual values see FIG. 7.

[0117] A highly significant drop in the group receiving HRT is seen after 12 months (P<0.001).

[0118] All cited patents, patent applications and literature are incorporated by reference in their entirety. In case of conflict, however, the present disclosure controls.

[0119] The invention has been described above by reference to specific embodiments It will be apparent to those skilled in the art, however, that many additions, deletions and modifications are possible without departing from the spirit of the invention as claimed below.

[0120] Collagen alpha 1(I) chain precursor—Human (fragments) Homo sapiens (man) Number of residues=1341

1 M F S F V D L R L L L L L A A T A L L T H G Q E E G Q V E G  
 5 10 15 20 25 30  
 31 Q D E D I P P I T C V Q N G L R Y H D R D V W K P E P C Q I  
 61 C V C D N G K V L C D D V I C D E T K N C P G A E V P E G E  
 91 C C P V C P D G S E S P T D Q E T T G V E G P K G D T G P R  
 121 G P R G P A G P P G R D G I P G Q P G L P G P P G P P G P P  
 151 G P P G L G G N F A P Q L S Y G Y D E K S T G G I S V P G P  
 181 M(G P S G P R G L P G P P G A P G P Z G F Z G P P G Z P G Z  
 211 P G A S G P)M(G P R G P P G P P G K B G B B G Z A G K P G R  
 241 P G Z R G P P G P Z G A R G L P G T A G L P)G M K G H R(G F  
 271 S G L B G A K G B A G P A G P K G Z P G S P G Z B G A P G Z)  
 301 M\G P P G P K G N S G E P G A P G S K G D T G A K G E P G P  
 331 V G V Q G P P G P A G E E G K R G A R G E P G P T G L P G P  
 361 P G E R G G P G S R G F P G A D G V A G P K G P A G E R G S  
 391 P G P A G P K G S P G E A G R P G E A G L P G A K G L T G S  
 421 P G S P G P D G K T G P P G P A G Q D G R P G P P G P P G A

-continued

451 R G Q A G V M G F P G P K G A A G E P G K A G E R G V P G P  
 481 P G A V G P A G K D G E A G A Q G P P G P A G P A G E R G E  
 511 Q G P A G S P G F Q G L P G P A G P P G E A G K P G E Q G V  
 541 P G D L G A P G P S G A R G E R G F P G E R G V Q G P P G P  
 571 A G P R G A N G A P G N D G A K G D A G A P G A P G S Q G A  
 601 P G L Q G M P G E R G A A G L P G P K G D R G D A G P K G A  
 631 D G S P G K D G V R G L T G P I G P P G P A G A P G D K G E  
 661 S G P S G P A G P T G A R G A P G D R G E P G P P G P A G F  
 691 A G P P G A D G Q P G A K G E P G D A G A K G D A G P P G P  
 721 A G P A G P P G P I G N V G A P G A K G A R G S A G P P G A  
 751 T G F P G A A G R V G P P G P S G N A G P P G P P G P A G K  
 781 E G G K G P R G E T G P A G R P G E V G P P G P P G P A G E  
 811 K G S P G A D G P A G A P G T P G P Q G I A G Q R G V V G L  
 841 P G Q R G E R G F P G L P G P S G E P G K Q G P S G A S G E  
 871 R G P P G P M G P P G L A G P P G E S G R E G A P G A E G S  
 901 P G R D G S P G A K G D R G E T G P A G P P G A X G A X G A  
 931 P G P V G P A G K S G D R G E T G P A G P A G P V G P A G A  
 961 R G P A G P Q G P R G D K G E T G E Q G D R G I K G H R G F  
 991 S G L Q G P P G P P G S P G E Q G P S G A S G P A G P R G P  
 1021 P G S A G A P G K D G L N G L P G P I G P P G P R G R T G D  
 1051 A G P V G P P G P P G P P G P P S A G F D F S F L P Q  
 1081 P P Q E K A H D G G R Y Y R A D D A N V V R D R D L E V D T  
 1111 T L K S L S Q Q I E N I R S P E G X R K N P A R T C R D L K  
 1141 M C H S D W K S G E Y W I D P N Q G C N L D A I K V F C N M  
 1171 E T G E T C V Y P T Q P S V A Q K N W Y I S K N P K D K R H  
 1201 V W F G E S M T D G F Q F E Y G G Q G S D P A D V A I Q L T  
 1231 F L R L M S T E A S Q N I T Y H C K N S V A Y M D Q Q T G N  
 1261 L K K A L L L X G S N E I E I R A E G N S R F T Y S V T V D  
 1291 G C T S H T G A W G K T V I E Y K T T K S S R L P I I D V A  
 1321 P L D V G A P D Q E F G F D V G P V C F L

[0121] Sequence of collagen alpha 1(I) chain precursor prepared from:

[0122] Chu, M. L., de Wet, W., Bernard, M., Ding, J. F., Morabito, M., Myers, J., Williams, C., and Ramirez, F., *Nature* 310, 337-340, 1984 (Human, sequence of residues 1-181 translated from the DNA sequence)

[0123] Click, E. M., and Bornstein, P., *Biochemistry* 9, 4699-4706, 1970 (Human skin, CNBr0-1, CNBr2, CNBr4, CNBr5, partial sequence of residues 162-301)

[0124] Morgan, P. H., Jacobs, H. G., Segrest, J. P., and Cunningham, L. W., *J. Biol. Chem.* 245, 5042-5048, 1970 (Human skin, sequence of residues 263-268)

[0125] Bernard, M. P., Chu, M. L., Myers, J. C., Ramirez, F., Eikenberry, E. F., and Prockop, D. J., *Biochemistry* 22, 5213-5223, 1983 (Sequence of residues 302-1341 translated from the mRNA sequence)

[0126] Procollagen alpha 2(I) chain precursor Homo sapiens (man) Number of residues=1366

1 M L S F V D T R T L L L L A V T L C L A T C Q S L Q E E T V  
31 R K G P A G D R G P R G E R G P P G P P G R D G E D G P T G  
61 P P G P P G P P G P P G L G G N F A A Q Y D G K G V G L G P  
91 G P M G L M G P R G P P G A A G A P G P Q G F Q G P A G E P  
121 G E P G Q T G P A G A R G P A G P P G K A G E D G H P G K P  
151 G R P G E R G V V G P Q G A R G F P G T P G L P G F K G I R  
181 G H N G L D G L K G Q P G A P G V K G E P G A P G E N G T P  
211 G Q T G A R G L P G E R G R V G A P G P A G A R G S D G S V  
241 G P V G P A G P N G S A G P P G F P G A P G P K G E I G A V  
271 G N A G P T G P A G P R G E V G L P G L S G P V G P P G N P  
301 G A N G L T G A K G A A G L P G V A G A P G L P G P R G I P  
331 G P P G A A G T T G A R G L V G E P G P A G S K G E S G N K  
361 G E P G S A G P Q G P P G P S G E E G K R G P N G E A G S A  
391 G P P G P P G L R G S P G S R G L P G A D G R A G V M G P P  
421 G S R G A S G P A G V R G P N G D A G R P G E P G L M G P R  
451 G L P G S P G N I G P A G K E G P V G L P G I D G R P G P I  
481 G P V G A R G E P G N I G F P G P K G P T G D P G K N G D K  
511 G H A G L A G A R G A P G P D G N N G A Q G P P G P Q G V Q  
541 G G K G E Q G P A G P P G F Q G L P G P S G P A G E V G K P  
571 G E R G L H G E F G L P G P A G P R G E R G P P G E S G A A  
601 G P T G P I G S R G P S G P P G P D G N K G E P G V V G A V  
631 G T A G P S G P S G L P G E R G A A G I P G G K G E K G E P  
661 G L R G E I G N P G R D G A R G A H G A V G A P G P A G A T  
691 G D R G E A G A A G P A G P A G P R G S P G E R G E V G P A  
721 G P N G F A G P A G A A G Q P G A K G E R G G K G P K G E N  
751 G V V G P T G P V G A A G P A G P N G P P G P A G S R G D G  
781 G P P G M T G F P G A A G R T G P P G P S G I S G P P G P P  
811 G P A G K E G L R G P R G D Q G P V G R T G E V G A V G P P  
841 G F A G E K G P S G E A G T A G P P G T P G P Q G L L G A P  
871 G I L G L P G S R G E R G L P G V A G A V G E P G P L G I A  
901 G P P G A R G P P G A V G S P G V N G A P G E A G R D G N P  
931 G N D G P P G R D G Q P G H K G E R G Y P G N I G P V G A A  
961 G A P G P H G P V G P A G K H G N R G E T G P S G P V G P A  
991 G A V G P R G P S G P Q G I R G D K G E P G E K G P R G L P  
1021 G F K G H N G L Q G L P G I A G H H G D Q G A P G S V G P A  
1051 G P R G P A G P S G P A G K D G R T G H P G T V G P A G I R  
1081 G P Q G H Q G P A G P P G P P G P P G P P G V S G G G Y D F  
1111 G Y D G D F Y R A D Q P R S A P S L R P K D Y E V D A T L K

-continued

1141 S L N N Q I E T L L T P E G S R K N P A R T C R D L R L S H  
 1171 P E W S S G Y Y W I D P N Q G C T M E A I K V Y C D F P T G  
 1201 E T C I R A Q P E N I P A K N W Y R S S K D K K H V W L G E  
 1231 T I N A G S Q F E Y N V E G V T S K E M A T Q L A F M R L L  
 1261 A N Y A S Q N I T Y H C K N S I A Y M D E E T G N L K K A V  
 1291 I L Q G S N D V E L V A E G N S R F T Y T V L V D G C S K K  
 1321 T N E W G K T I I E Y K T N K P S R L P F L D I A P L D I G  
 1351 G A D H E F F V D I G P V C F K

[0127] Sequence of procollagen alpha 2(I) chain precursor prepared from:

[0128] de Wet, W., Bernard, M., Benson-Chanda, V., Chu, M. L., Dickson, L., Weil, D., and Ramirez, F., J. Biol. Chem. 262, 16032-16036, 1987 (Sequence trans-

lated from the mRNA sequence) Title: Organization of the human pro-alpha-2(I) collagen gene.

[0129] Collagen alpha 1(II) chain precursor Homo sapiens (man) Number of residues=1418

1 MIRLGAPQSL VLLTLLVAAV LRCQGQDVRQ PGPKGQKGEF GDIKDIVGPK  
 51 GPPGPQGPAG EQGPRGDRGD KGEKGAPGPR GRDGEPGTLG NPGPPGPPGF  
 101 PGPPGLGNF AAQMAGGFDE KAGGAQLGVM QGPMGPMGPR GPPGPAGAPG  
 151 PQGFQGNPGE PGEPGVSGPM GPRGPPGPPG KPGDDGEAGK PGKAGERGPP  
 201 GPQGARGFPF TPGLPGVKGH RGYPLDGAK GEAGAPGVKG ESGSPGENGS  
 251 PGPMGPRGLP GERGRTGPAG AAGARGNDGQ PGFAGPPGPV GPAGGPFPG  
 301 APGAKGEAGP TGARGPEGAQ GPRGEPGTPG SPGPAGASGN PGTDGIPGAK  
 351 GSAGAPGIAG APGFPGPRGP PDPQGATGPI GPKGQTGKPG IAGFKGEQGP  
 401 KGEPGPAGPQ GAPGPAGEEG KRGARGEPPG VGPIGPPGER GAPNRRGFPF  
 451 QDGLAGPKGA PGERGPSGLA GPKGANGDPG RPEEPGLPGA RGLTGRPGDA  
 501 GEQGVGPPSG APGEDGRFPG PGPOGARGQP GVMGFPKPKG ANGEPPKAGE  
 551 KGLPGAPGLR GLPGKDGETG AEGPPGAPG AGERGEQGAP GPSGFQGLPG  
 601 PPGPPGEGGK PGDQGVVPEA GAPGLVGPGR ERGFPGERGS PGAQGLQGPR  
 651 GLPGTPGTDG PKGASGPAGP PGAQGGPGLQ GMPGERGAAG IAGPKGDRGD  
 701 VGEKGEPEGAP GKDGGRLTG PIGPPGAGA NGEKGEVGGP GPAGSAGARG  
 751 APGERGETGP PGTSGIAGPP GADGQPGAK EQGEAGQKGD AGAPGPQGPS  
 801 GAPGPQGPTG VTGPKGARGA QGPPGATGFP GAAGRVPVGG SNGNPPGPPG  
 851 PGPSGKDGEK GARGDSGPPG RAGEPGLQGP AGPPGEKGEF GDDGPSGAEG  
 901 PPGPQGLAGQ RGIVGLPGQR GERGFPLPG PSGEPPQQA PGASGDRGPP  
 951 GPVGPPLTG PAGEPREGS PGADGPPGRD GAAGVKGDRG ETGAVGAPGA  
 1001 PGPPGSPGPA GPTGKQGDRG EAGAQQPMGP SGPAGARGIQ GPQGRGDKG  
 1051 EAGEPGERGL KHRGFTGLQ GLPGPPGPPG DQGASGPAGP SGPRGPPGPPV  
 1101 GPSGKDANG IPGPIGPPGP RGRSGETGPA GPPGNPVPV PPGPPGPPID  
 1151 MSAFAGLGR EKGPDPQYM RADQAAGLR QHDAEVDATL KSLNNQIESI  
 1201 RSPGSRKNP ARTCRDLKLC HPEWKSQDYW IDPNQGCTLD AMKVFCNMET

-continued

1251 GETCVYPNPA NVPKKNWSS KSKEKKHIWF GETINGGFHF SYGDDNLAPN  
 1301 TANVQMTFLR LLSTEGSQNI THYCKNSIAY LDEAAGNLKK ALLIQGSNDV  
 1351 EIRAEGNSRF TYTALKDGCT KHTGKWGKTV IEYRSQKTSR LPIIDIAPMD  
 1401 IGGPEQEFV DIGVCFL

[0130] Sequence of collagen alpha 1(II) chain precursor prepared from:

[0131] Su, M. W., Lee, B., Ramirez, F., Machado, M., and Horton, W. Nucleic Acids Res 17, 9473, 1989 Nucleotide sequence of the full length cDNA encoding for human type II procollagen.

[0132] Baldwin, C. T., Reginato, A. M., Smith, C., Jimenez, S. A., and Prockop, D. J., Biochem. J. 262, 521-528, 1989 Structure of cDNA clones coding for human type II procollagen The alpha-1(II) chain is more similar to the alpha-1(I) chain than two other alpha chains of fibrillar collagens.

[0133] Ala-Kokko, L., Baldwin, C. T., Moskowitz, R. W., and Prockop, D. J. Proc. Natl. Acad. Sci. U.S.A. 87, 6565-6568, 1990 Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia.

[0134] Ramirez, F. submitted to the EMBL Data Library, December 1988 Reference number: S04892

[0135] Vikkula, M., and Peltonen, L. FEBS Lett. 250, 171-174, 1989 Structural analyses of the polymorphic area in type II collagen gene.

[0136] Collagen alpha 1(III) chain precursor Homo sapiens (man) Number of residues=1078

	5	10	15	20	25	30
1	\Q	N	Y	S	P	Q
	Y	D	S	Y	D	V
	K	S	G	G	V	A
	V	G	G	L	A	G
	Y	P	G	P	A	G
31	P	P	G	P	P	G
	P	G	T	S	G	H
	P	G	S	P	G	S
	P	G	Y	Q	G	P
	P	G	E	P	G	
61	Q	A	G	P	S	G
	P	P	G	P	P	G
	A	I	G	P	S	G
	P	A	G	K	D	G
	E	S	G	R	P	C
91	R	P	G	D	R	G
	L	P	G	P	P	G
	I	K	G	P	A	G
	I	P	G	F	P	G
	M	K	G	H	R	G
121	F	D	G	R	N	G
	E	K	G	E	T	G
	A	P	G	L	K	G
	E	N	G	L	P	G
	E	N	G	A	P	G
151	P	M	G	P	R	G
	A	P	G	E	R	G
	R	P	G	L	P	G
	A	A	G	A	R	G
	N	D	G	A	R	G
181	S	D	G	Q	P	G
	P	P	G	P	P	G
	T	A	G	F	P	G
	S	P	G	A	K	G
	E	F	G	P	A	G
211	S	P	G	S	N	G
	A	P	G	Q	R	G
	E	P	G	P	Q	G
	H	A	G	A	Q	G
	P	P	G	P	P	G
241	I	N	G	S	P	G
	G	K	G	E	M	G
	P	A	G	I	P	G
	A	P	G	L	M	G
	A	R	G	P	P	G
271	P	A	G	A	N	G
	A	P	G	L	R	G
	G	A	G	E	P	G
	K	N	G	A	K	G
	E	P	G	P	R	G
301	E	R	G	E	A	G
	I	P	G	V	P	G
	A	K	G	E	D	G
	K	D	G	S	P	G
	D	P	G	A	N	G
331	L	P	G	A	A	G
	E	R	G	A	L	G
	S	R	G	P	A	G
	P	N	G	I	P	G
	E	K	G	P	A	G
361	E	R	G	A	P	G
	P	A	G	P	R	G
	A	A	G	E	P	G
	R	D	G	V	P	G
	G	P	G	M	R	G
391	M	P	G	S	P	G
	G	P	G	S	D	G
	K	P	G	P	P	G
	S	Q	G	E	S	G
	R	P	G	P	P	G
421	P	S	G	P	R	G
	Q	P	G	V	M	G
	F	P	G	P	K	G
	N	D	G	A	P	G
	K	N	G	E	R	G
451	G	P	G	G	P	Q
	G	P	P	G	K	N
	G	E	Y	G	P	Q
	G	P	P	G	P	T
	G	P	G	P	G	P
481	D	K	G	D	T	G
	P	R	G	P	Q	G
	L	Q	G	L	P	G
	T	G	G	P	P	G
	E	N	G	K	P	G
511	E	P	G	P	K	G
	E	A	G	A	P	G
	A	P	G	G	K	G
	D	A	G	A	P	G
	E	R	G	P	P	G
541	L	A	G	A	P	G
	L	R	G	G	A	G
	P	P	G	P	E	G
	G	K	G	A	A	G
	P	P	G	P	P	G
571	A	A	G	T	P	G
	L	Q	G	M	P	G
	E	R	G	G	L	G
	S	P	G	P	K	G
	D	K	G	E	P	G
601	G	P	G	A	D	G
	V	P	G	K	D	G
	P	R	G	P	T	G
	P	I	G	P	P	G
	P	A	G	Q	P	G
631	D	K	G	E	G	A
	P	G	L	P	G	I
	A	G	P	R	G	S
	P	G	E	R	G	E
	T	G	P	P	G	
661	P	A	G	F	P	G
	A	P	G	Q	N	G
	E	P	G	K	G	E
	R	G	A	P	G	E
	K	G	E	G	G	

## -continued

691 P P G V A G P P G G S G P A G P P G P Q G V K G E R G S P G  
721 G P G A A G F P G A R G L P G P P G S N G N P G P P G P S G  
751 S P G K D G P P G P A G N T G A P G S P G V S G P K G D A G  
781 Q P G E K G S P G A Q G P P G A P G P L G I A G I T G A R G  
811 L A G P P G M P G P R G S P G P Q G V K G E S G K P G A N G  
841 L S G E R G P P G P Q G L P G L A G T A G E P G R D G N P G  
871 S D G L P G R D G S P G G K G D R G E N G S P G A P G A P G  
901 H P G P P G P V G P A G K S G D R G E S G P A G P A G A P G  
931 P A G S R G A P G P Q G P R G D K G E T G E R G A A G I K G  
961 H R G F P G N P G A P G S P G P A G Q Q G A I G S P G P A G  
991 P R G P V G P S G P P G K D G T S G H P G P I G P P G P R G  
1021 N R G E R G S E G S P G H P G Q S G P P G P P G A P G P C C  
1051 G G V G A P A I A G I G A E K A G G F A P Y Y G D E P M \

[0137] Sequence of collagen alpha 1(III) chain precursor prepared from:

[0138] Janeczko, R. A., and Ramirez, F., Nucleic Acids Res. 17, 6742, 1989 Nucleotide and amino acid sequences of the entire human alpha-1 (III) collagen.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 21

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: N-terminal

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (vii) IMMEDIATE SOURCE:

(B) CLONE: COLLAGEN TYPE I-alpha 1 -N term

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Asp Glu Lys Ser Thr Gly Gly  
1 5

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide



-continued

---

(B) CLONE: COLLAGEN TYPE I -ALPHA 1 NEAR c

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Gly Ile Lys Gly His Arg  
1 5

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:  
(B) CLONE: COLLAGEN TYPE I- ALPHA 2- NEAR N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Gly Phe Lys Gly Ile Arg  
1 5

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 9 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:  
(B) CLONE: COLLAGEN TYPE I - ALPHA 2 - NEAR C

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Gly Leu Pro Gly Leu Lys Gly His Asn  
1 5

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:  
(B) CLONE: COLLAGEN TYPE II- ALPHA 1- N TERM

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Pro Gly Pro Lys Gly Glu  
1 5

---

-continued

---

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: COLLAGEN TYPE II- ALPHA 1 N2
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Gly Gln Lys Gly Glu Pro  
1 5

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: COLLAGEN TYPE II - ALPHA 1- N3
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Gly Asp Ile Lys Asp Ile Val  
1 5

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: C-terminal
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: COLLAGEN TYPE II - ALPHA 1 -C TERM
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Glu Lys Gly Pro Asp  
1 5

(2) INFORMATION FOR SEQ ID NO: 12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

---

-continued

---

- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: COLLAGEN TYPE II - ALPHA 1 - NEAR N
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Gly Val Lys  
1

- (2) INFORMATION FOR SEQ ID NO: 13:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 5 amino acids
    - (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (v) FRAGMENT TYPE: internal
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: Homo sapiens
  - (vii) IMMEDIATE SOURCE:
    - (B) CLONE: COLLAGEN TYPE II - ALPHA 1 -NEAR N2
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Pro Gly Val Lys Gly  
1 5

- (2) INFORMATION FOR SEQ ID NO: 14:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 6 amino acids
    - (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (v) FRAGMENT TYPE: N-terminal
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: Homo sapiens
  - (vii) IMMEDIATE SOURCE:
    - (B) CLONE: COLLAGEN TYPE III -ALPHA 1 - N TERM
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Asp Val Lys Ser Gly Val  
1 5

- (2) INFORMATION FOR SEQ ID NO: 15:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 7 amino acids
    - (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (v) FRAGMENT TYPE: C-terminal
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: Homo sapiens



-continued

---

Ala Leu Leu Thr His Gly Gln Glu Glu Gly Gln Val Glu Gly Gln Asp  
                   20                                  25                                  30

Glu Asp Ile Pro Pro Ile Thr Cys Val Gln Asn Gly Leu Arg Tyr His  
                   35                                  40                                  45

Asp Arg Asp Val Trp Lys Pro Glu Pro Cys Gln Ile Cys Val Cys Asp  
                   50                                  55                                  60

Asn Gly Lys Val Leu Cys Asp Asp Val Ile Cys Asp Glu Thr Lys Asn  
                   65                                  70                                  75                                  80

Cys Pro Gly Ala Glu Val Pro Glu Gly Glu Cys Cys Pro Val Cys Pro  
                                   85                                  90

Asp Gly Ser Glu Ser Pro Thr Asp Gln Glu Thr Thr Gly Val Glu Gly  
                   100                                  105                                  110

Pro Lys Gly Asp Thr Gly Pro Arg Gly Pro Arg Gly Pro Ala Gly Pro  
                   115                                  120                                  125

Pro Gly Arg Asp Gly Ile Pro Gly Gln Pro Gly Leu Pro Gly Pro Pro  
                   130                                  135                                  140

Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala  
                   145                                  150                                  155                                  160

Pro Gln Leu Tyr Gly Tyr Asp Glu Lys Ser Thr Gly Gly Ile Ser Val  
                                   165                                  170                                  175

Pro Gly Pro Met Gly Pro Ser Gly Pro Arg Gly Leu Pro Gly Pro Pro  
                   180                                  185                                  190

Gly Ala Pro Gly Pro Glx Gly Phe Glx Gly Pro Pro Gly Glx Pro Gly  
                   195                                  200                                  205

Glx Pro Gly Ala Ser Gly Pro Met Gly Pro Arg Gly Pro Pro Gly Pro  
                   210                                  215                                  220

Pro Gly Lys Asx Gly Asx Asx Gly Glx Ala Gly Lys Pro Gly Arg Pro  
                   225                                  230                                  235                                  240

Gly Glx Arg Gly Pro Pro Gly Pro Glx Gly Ala Arg Gly Leu Pro Gly  
                                   245                                  250                                  255

Thr Ala Gly Leu Pro Gly Met Lys Gly His Arg Gly Phe Ser Gly Leu  
                   260                                  265                                  270

Asx Gly Ala Lys Gly Asx Ala Gly Pro Ala Gly Pro Lys Gly Glx Pro  
                   275                                  280                                  285

Gly Ser Pro Gly Glx Asx Gly Ala Pro Gly Glx Met Gly Pro Pro Gly  
                   290                                  295                                  300

Pro Lys Gly Asn Ser Gly Glu Pro Gly Ala Pro Gly Ser Lys Gly Asp  
                   305                                  310                                  315                                  320

Thr Gly Ala Lys Gly Glu Pro Gly Pro Val Gly Val Gln Gly Pro Pro  
                                   325                                  330                                  335

Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu Pro Gly  
                   340                                  345                                  350

Pro Thr Gly Leu Pro Gly Pro Pro Gly Glu Arg Gly Gly Pro Gly Ser  
                   355                                  360                                  365

Arg Gly Phe Pro Gly Ala Asp Gly Val Ala Gly Pro Lys Gly Pro Ala  
                   370                                  375                                  380

Gly Glu Arg Gly Ser Pro Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly  
                   385                                  390                                  395                                  400

Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro Gly Ala Lys Gly Leu  
                                   405                                  410                                  415

Thr Gly Ser Pro Gly Ser Pro Gly Pro Asp Gly Lys Thr Gly Pro Pro

-continued

420			425			430									
Gly	Pro	Ala	Gly	Gln	Asp	Gly	Arg	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly
		435					440					445			
Ala	Arg	Gly	Gln	Ala	Gly	Val	Met	Gly	Phe	Pro	Gly	Pro	Lys	Gly	Ala
		450					455				460				
Ala	Gly	Glu	Pro	Gly	Lys	Ala	Gly	Glu	Arg	Gly	Val	Pro	Gly	Pro	Pro
		465			470					475					480
Gly	Ala	Val	Gly	Pro	Ala	Gly	Lys	Asp	Gly	Glu	Ala	Gly	Ala	Gln	Gly
				485						490				495	
Pro	Pro	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Glu	Arg	Gly	Glu	Gln	Gly	Pro
				500				505					510		
Ala	Gly	Ser	Pro	Gly	Phe	Gln	Gly	Leu	Pro	Gly	Pro	Ala	Gly	Pro	Pro
		515						520					525		
Gly	Glu	Ala	Gly	Lys	Pro	Gly	Glu	Gln	Gly	Val	Pro	Gly	Asp	Leu	Gly
		530					535				540				
Ala	Pro	Gly	Pro	Ser	Gly	Ala	Arg	Gly	Glu	Arg	Gly	Phe	Pro	Gly	Glu
		545			550					555					560
Arg	Gly	Val	Gln	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Ala	Asn
				565						570				575	
Gly	Ala	Pro	Gly	Asn	Asp	Gly	Ala	Lys	Gly	Asp	Ala	Gly	Ala	Pro	Gly
				580				585					590		
Ala	Pro	Gly	Ser	Gln	Gly	Ala	Pro	Gly	Leu	Gln	Gly	Met	Pro	Gly	Glu
		595					600						605		
Arg	Gly	Ala	Ala	Gly	Leu	Pro	Gly	Pro	Lys	Gly	Asp	Arg	Gly	Asp	Ala
		610					615				620				
Gly	Pro	Lys	Gly	Ala	Asp	Gly	Ser	Pro	Gly	Lys	Asp	Gly	Val	Arg	Gly
		625			630					635					640
Leu	Thr	Gly	Pro	Ile	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Ala	Pro	Gly	Asp
				645						650				655	
Lys	Gly	Glu	Ser	Gly	Pro	Ser	Gly	Pro	Ala	Gly	Pro	Thr	Gly	Ala	Arg
				660				665					670		
Gly	Ala	Pro	Gly	Asp	Arg	Gly	Glu	Pro	Gly	Pro	Pro	Gly	Pro	Ala	Gly
		675					680						685		
Phe	Ala	Gly	Pro	Pro	Gly	Ala	Asp	Gly	Gln	Pro	Gly	Ala	Lys	Gly	Glu
		690					695				700				
Pro	Gly	Asp	Ala	Gly	Ala	Lys	Gly	Asp	Ala	Gly	Pro	Pro	Gly	Pro	Ala
		705			710					715					720
Gly	Pro	Ala	Gly	Pro	Pro	Gly	Pro	Ile	Gly	Asn	Val	Gly	Ala	Pro	Gly
				725						730				735	
Ala	Lys	Gly	Ala	Arg	Gly	Ser	Ala	Gly	Pro	Pro	Gly	Ala	Thr	Gly	Phe
				740				745					750		
Pro	Gly	Ala	Ala	Gly	Arg	Val	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Asn	Ala
		755					760						765		
Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Lys	Glu	Gly	Gly	Lys	Gly
		770					775				780				
Pro	Arg	Gly	Glu	Thr	Gly	Pro	Ala	Gly	Arg	Pro	Gly	Glu	Val	Gly	Pro
		785			790					795					800
Pro	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Glu	Lys	Gly	Ser	Pro	Gly	Ala	Asp
				805						810				815	
Gly	Pro	Ala	Gly	Ala	Pro	Gly	Thr	Pro	Gly	Pro	Gln	Gly	Ile	Ala	Gly
				820				825					830		

-continued

---

Gln Arg Gly Val Val Gly Leu Pro Gly Gln Arg Gly Glu Arg Gly Phe  
 835 840 845  
 Pro Gly Leu Pro Gly Pro Ser Gly Glu Pro Gly Lys Gln Gly Pro Ser  
 850 855 860  
 Gly Ala Ser Gly Glu Arg Gly Pro Pro Gly Pro Met Gly Pro Pro Gly  
 865 870 875 880  
 Leu Ala Gly Pro Pro Gly Glu Ser Gly Arg Glu Gly Ala Pro Gly Ala  
 885 890 895  
 Glu Gly Ser Pro Gly Arg Asp Gly Ser Pro Gly Ala Lys Gly Asp Arg  
 900 905 910  
 Gly Glu Thr Gly Pro Ala Gly Pro Gly Ala Xaa Gly Ala Xaa Gly  
 915 920 925  
 Ala Pro Gly Pro Val Gly Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu  
 930 935 940  
 Thr Gly Pro Ala Gly Pro Ala Gly Pro Val Gly Pro Ala Gly Ala Arg  
 945 950 955 960  
 Gly Pro Ala Gly Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly  
 965 970 975  
 Glu Gln Gly Asp Arg Gly Ile Lys Gly His Arg Gly Phe Ser Gly Leu  
 980 985 990  
 Gln Gly Pro Pro Gly Pro Pro Gly Ser Pro Gly Glu Gln Gly Pro Ser  
 995 1000 1005  
 Gly Ala Ser Gly Pro Ala Gly Pro Arg Gly Pro Pro Gly Ser Ala Gly  
 1010 1015 1020  
 Ala Pro Gly Lys Asp Gly Leu Asn Gly Leu Pro Gly Pro Ile Gly Pro  
 1025 1030 1035 1040  
 Pro Gly Pro Arg Gly Arg Thr Gly Asp Ala Gly Pro Val Gly Pro Pro  
 1045 1050 1055  
 Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Ser Ala Gly Phe  
 1060 1065 1070  
 Asp Phe Ser Phe Leu Pro Gln Pro Pro Gln Glu Lys Ala His Lys Gly  
 1075 1080 1085  
 Gly Arg Tyr Tyr Arg Ala Asp Asp Ala Asn Val Val Arg Asp Arg Asp  
 1090 1095 1100  
 Leu Glu Val Asp Thr Thr Leu Lys Ser Leu Ser Gln Gln Ile Glu Asn  
 1105 1110 1115 1120  
 Ile Arg Ser Pro Glu Gly Xaa Arg Lys Asn Pro Ala Arg Thr Cys Arg  
 1125 1130 1135  
 Asp Leu Lys Met Cys His Ser Asp Trp Lys Ser Gly Glu Tyr Trp Ile  
 1140 1145 1150  
 Asp Pro Asn Gln Gly Cys Asn Leu Asp Ala Ile Lys Val Phe Cys Asn  
 1155 1160 1165  
 Met Glu Thr Gly Glu Thr Cys Val Tyr Pro Thr Gln Pro Ser Val Ala  
 1170 1175 1180  
 Gln Lys Asn Trp Tyr Ile Ser Lys Asn Pro Lys Asp Lys Asp Arg His  
 1185 1190 1195 1200  
 Val Trp Phe Gly Glu Ser Met Thr Asp Gly Phe Gln Phe Glu Tyr Gly  
 1205 1210 1215  
 Gly Gln Gly Ser Asp Pro Ala Asp Val Ala Ile Gln Leu Thr Phe Leu  
 1220 1225 1230

-continued

---

Arg Leu Met Ser Thr Glu Ala Ser Gln Asn Ile Thr Tyr His Cys Lys  
 1235 1240 1245

Asn Ser Val Ala Tyr Met Asp Gln Gln Thr Gly Asn Leu Lys Lys Ala  
 1250 1255 1260

Leu Leu Leu Xaa Gly Ser Asn Glu Ile Glu Ile Arg Ala Glu Gly Asn  
 1265 1270 1275 1280

Ser Arg Phe Thr Tyr Ser Val Thr Val Asp Gly Cys Thr Ser His Thr  
 1285 1290 1295

Gly Ala Trp Gly Lys Thr Val Ile Glu Tyr Lys Thr Thr Lys Ser Ser  
 1300 1305 1310

Arg Leu Pro Ile Ile Asp Val Ala Pro Leu Asp Val Gly Ala Pro Asp  
 1315 1320 1325

Gln Glu Phe Gly Phe Asp Val Gly Pro Val Cys Phe Leu  
 1330 1335 1340

## (2) INFORMATION FOR SEQ ID NO: 19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1366 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: collagen alpha 2- type I

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Met Leu Ser Phe Val Asp Thr Arg Thr Leu Leu Leu Leu Ala Val Thr  
 1 5 10 15

Leu Cys Leu Ala Thr Cys Gln Ser Leu Gln Glu Glu Thr Val Arg Lys  
 20 25 30

Gly Pro Ala Gly Asp Arg Gly Pro Arg Gly Glu Arg Gly Pro Pro Gly  
 35 40 45

Pro Pro Gly Arg Asp Gly Glu Asp Gly Pro Thr Gly Pro Pro Gly Pro  
 50 55 60

Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala Gln  
 65 70 75 80

Tyr Asp Gly Lys Gly Val Gly Leu Gly Pro Gly Pro Met Gly Leu Met  
 85 90 95

Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly Pro Gln Gly  
 100 105 110

Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro  
 115 120 125

Ala Gly Ala Arg Gly Pro Ala Gly Pro Pro Gly Lys Ala Gly Glu Asp  
 130 135 140

Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val Val Gly  
 145 150 155 160

Pro Gln Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Phe  
 165 170 175

Lys Gly Ile Arg Gly His Asn Gly Leu Asp Gly Leu Lys Gly Gln Pro  
 180 185 190

Gly Ala Pro Gly Val Lys Gly Glu Pro Gly Ala Pro Gly Glu Asn Gly

-continued

195		200		205											
Thr	Pro	Gly	Gln	Thr	Gly	Ala	Arg	Gly	Leu	Pro	Gly	Glu	Arg	Gly	Arg
210						215					220				
Val	Gly	Ala	Pro	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Ser	Asp	Gly	Ser	Val
225					230					235					240
Gly	Pro	Val	Gly	Pro	Ala	Gly	Pro	Asn	Gly	Ser	Ala	Gly	Pro	Pro	Gly
				245					250					255	
Phe	Pro	Gly	Ala	Pro	Gly	Pro	Lys	Gly	Glu	Ile	Gly	Ala	Val	Gly	Asn
			260					265					270		
Ala	Gly	Pro	Thr	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Glu	Val	Gly	Leu	Pro
			275				280					285			
Gly	Leu	Ser	Gly	Pro	Val	Gly	Pro	Pro	Gly	Asn	Pro	Gly	Ala	Asn	Gly
	290					295					300				
Leu	Thr	Gly	Ala	Lys	Gly	Ala	Ala	Gly	Leu	Pro	Gly	Val	Ala	Gly	Ala
305					310					315					320
Pro	Gly	Leu	Pro	Gly	Pro	Arg	Gly	Ile	Pro	Gly	Pro	Pro	Gly	Ala	Ala
				325					330					335	
Gly	Thr	Thr	Gly	Ala	Arg	Gly	Leu	Val	Gly	Glu	Pro	Gly	Pro	Ala	Gly
			340					345					350		
Ser	Lys	Gly	Glu	Ser	Gly	Asn	Lys	Gly	Glu	Pro	Gly	Ser	Ala	Gly	Pro
		355					360					365			
Gln	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Glu	Glu	Gly	Lys	Arg	Gly	Pro	Asn
	370					375					380				
Gly	Glu	Ala	Gly	Ser	Ala	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Leu	Arg	Gly
385					390					395					400
Ser	Pro	Gly	Ser	Arg	Gly	Leu	Pro	Gly	Ala	Asp	Gly	Arg	Ala	Gly	Val
				405					410					415	
Met	Gly	Pro	Pro	Gly	Ser	Arg	Gly	Ala	Ser	Gly	Pro	Ala	Gly	Val	Arg
			420					425					430		
Gly	Pro	Asn	Gly	Asp	Ala	Gly	Arg	Pro	Gly	Glu	Pro	Gly	Leu	Met	Gly
		435					440					445			
Pro	Arg	Gly	Leu	Pro	Gly	Ser	Pro	Gly	Asn	Ile	Gly	Pro	Ala	Gly	Lys
	450					455					460				
Glu	Gly	Pro	Val	Gly	Leu	Pro	Gly	Ile	Asp	Gly	Arg	Pro	Gly	Pro	Ile
465					470					475					480
Gly	Pro	Val	Gly	Ala	Arg	Gly	Glu	Pro	Gly	Asn	Ile	Gly	Phe	Pro	Gly
				485					490					495	
Pro	Lys	Gly	Pro	Thr	Gly	Asp	Pro	Gly	Lys	Asn	Gly	Asp	Lys	Gly	His
			500					505					510		
Ala	Gly	Leu	Ala	Gly	Ala	Arg	Gly	Ala	Pro	Gly	Pro	Asp	Gly	Asn	Asn
		515					520					525			
Gly	Ala	Gln	Gly	Pro	Pro	Gly	Pro	Gln	Gly	Val	Gln	Gly	Gly	Lys	Gly
	530					535					540				
Glu	Gln	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Phe	Gln	Gly	Leu	Pro	Gly	Pro
545					550					555					560
Ser	Gly	Pro	Ala	Gly	Glu	Val	Gly	Lys	Pro	Gly	Glu	Arg	Gly	Leu	His
				565					570					575	
Gly	Glu	Phe	Gly	Leu	Pro	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Glu	Arg	Gly
		580						585					590		
Pro	Pro	Gly	Glu	Ser	Gly	Ala	Ala	Gly	Pro	Thr	Gly	Pro	Ile	Gly	Ser
		595					600						605		

-continued

---

Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro  
 610 615 620  
 Gly Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser Gly Pro Ser Gly  
 625 630 635 640  
 Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile Pro Gly Gly Lys Gly Glu  
 645 650 655  
 Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile Gly Asn Pro Gly Arg Asp  
 660 665 670  
 Gly Ala Arg Gly Ala His Gly Ala Val Gly Ala Pro Gly Pro Ala Gly  
 675 680 685  
 Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro  
 690 695 700  
 Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala  
 705 710 715 720  
 Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly  
 725 730 735  
 Ala Lys Gly Glu Arg Gly Gly Lys Gly Pro Lys Gly Glu Asn Gly Val  
 740 745 750  
 Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn  
 755 760 765  
 Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly  
 770 775 780  
 Met Thr Gly Phe Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro  
 785 790 795 800  
 Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu  
 805 810 815  
 Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly  
 820 825 830  
 Glu Val Gly Ala Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro  
 835 840 845  
 Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln  
 850 855 860  
 Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly  
 865 870 875 880  
 Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro  
 885 890 895  
 Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val  
 900 905 910  
 Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly  
 915 920 925  
 Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His  
 930 935 940  
 Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala  
 945 950 955 960  
 Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly  
 965 970 975  
 Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala  
 980 985 990  
 Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys  
 995 1000 1005

-continued

---

Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Phe Lys Gly  
 1010 1015 1020  
 His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His Gly Asp  
 1025 1030 1035 1040  
 Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg Gly Pro Ala  
 1045 1050 1055  
 Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr Gly His Pro Gly  
 1060 1065 1070  
 Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro  
 1075 1080 1085  
 Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser  
 1090 1095 1100  
 Gly Gly Gly Tyr Asp Phe Gly Tyr Asp Gly Asp Phe Tyr Arg Ala Asp  
 1105 1110 1115 1120  
 Gln Pro Arg Ser Ala Pro Ser Leu Arg Pro Lys Asp Tyr Glu Val Asp  
 1125 1130 1135  
 Ala Thr Leu Lys Ser Leu Asn Asn Gln Ile Glu Thr Leu Leu Thr Pro  
 1140 1145 1150  
 Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu  
 1155 1160 1165  
 Ser His Pro Glu Trp Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln  
 1170 1175 1180  
 Gly Cys Thr Met Glu Ala Ile Lys Val Tyr Cys Asp Phe Pro Thr Gly  
 1185 1190 1195 1200  
 Glu Thr Cys Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp  
 1205 1210 1215  
 Tyr Arg Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile  
 1220 1225 1230  
 Asn Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys  
 1235 1240 1245  
 Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr Ala  
 1250 1255 1260  
 Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr Met Asp  
 1265 1270 1275 1280  
 Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln Gly Ser Asn  
 1285 1290 1295  
 Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe Thr Tyr Thr Val  
 1300 1305 1310  
 Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu Trp Gly Lys Thr Ile  
 1315 1320 1325  
 Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg Leu Pro Phe Leu Asp Ile  
 1330 1335 1340  
 Ala Pro Leu Asp Ile Gly Gly Ala Asp His Glu Phe Phe Val Asp Ile  
 1345 1350 1355 1360  
 Gly Pro Val Cys Phe Lys  
 1365

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1418 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

---

-continued

---

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: COLLAGEN -ALPHA 1 (II)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Met Ile Arg Leu Gly Ala Pro Gln Ser Leu Val Leu Leu Thr Leu Leu  
 1 5 10 15

Val Ala Ala Val Leu Arg Cys Gln Gly Gln Asp Val Arg Gln Pro Gly  
 20 25 30

Pro Lys Gly Gln Lys Gly Glu Pro Gly Asp Ile Lys Asp Ile Val Gly  
 35 40 45

Pro Lys Gly Pro Pro Gly Pro Gln Gly Pro Ala Gly Glu Gln Gly Pro  
 50 55 60

Arg Gly Asp Arg Gly Asp Lys Gly Glu Lys Gly Ala Pro Gly Pro Arg  
 65 70 75 80

Gly Arg Asp Gly Glu Pro Gly Thr Leu Gly Asn Pro Gly Pro Pro Gly  
 85 90 95

Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala  
 100 105 110

Gln Met Ala Gly Gly Phe Asp Glu Lys Ala Gly Gly Ala Gln Leu Gly  
 115 120 125

Val Met Gln Gly Pro Met Gly Pro Met Gly Pro Arg Gly Pro Pro Gly  
 130 135 140

Pro Ala Gly Ala Pro Gly Pro Gln Gly Phe Gln Gly Asn Pro Gly Glu  
 145 150 155 160

Pro Gly Glu Pro Gly Val Ser Gly Pro Met Gly Pro Arg Gly Pro Pro  
 165 170 175

Gly Pro Pro Gly Lys Pro Gly Asp Asp Gly Glu Ala Gly Lys Pro Gly  
 180 185 190

Lys Ala Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Phe  
 195 200 205

Pro Gly Thr Pro Gly Leu Pro Gly Val Lys Gly His Arg Gly Tyr Pro  
 210 215 220

Gly Leu Asp Gly Ala Lys Gly Glu Ala Gly Ala Pro Gly Val Lys Gly  
 225 230 235 240

Glu Ser Gly Ser Pro Gly Glu Asn Gly Ser Pro Gly Pro Met Gly Pro  
 245 250 255

Arg Gly Leu Pro Gly Glu Arg Gly Arg Thr Gly Pro Ala Gly Ala Ala  
 260 265 270

Gly Ala Arg Gly Asn Asp Gly Gln Pro Gly Pro Ala Gly Pro Pro Gly  
 275 280 285

Pro Val Gly Pro Ala Gly Gly Pro Gly Phe Pro Gly Ala Pro Gly Ala  
 290 295 300

Lys Gly Glu Ala Gly Pro Thr Gly Ala Arg Gly Pro Glu Gly Ala Gln  
 305 310 315 320

Gly Pro Arg Gly Glu Pro Gly Thr Pro Gly Ser Pro Gly Pro Ala Gly  
 325 330 335

Ala Ser Gly Asn Pro Gly Thr Asp Gly Ile Pro Gly Ala Lys Gly Ser  
 340 345 350

-continued

---

Ala Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly Phe Pro Gly Pro Arg  
355 360 365

Gly Pro Pro Asp Pro Gln Gly Ala Thr Gly Pro Leu Gly Pro Lys Gly  
370 375 380

Gln Thr Gly Lys Pro Gly Ile Ala Gly Phe Lys Gly Glu Gln Gly Pro  
385 390 395 400

Lys Gly Glu Pro Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Pro Ala  
405 410 415

Gly Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu Pro Gly Gly Val Gly  
420 425 430

Pro Ile Gly Pro Pro Gly Glu Arg Gly Ala Pro Gly Asn Arg Gly Phe  
435 440 445

Pro Gly Gln Asp Gly Leu Ala Gly Pro Lys Gly Ala Pro Gly Glu Arg  
450 455 460

Gly Pro Ser Gly Leu Ala Gly Pro Lys Gly Ala Asn Gly Asp Pro Gly  
465 470 475 480

Arg Pro Gly Glu Pro Gly Leu Pro Gly Ala Arg Gly Leu Thr Gly Arg  
485 490 495

Pro Gly Asp Ala Gly Pro Gln Gly Lys Val Gly Pro Ser Gly Ala Pro  
500 505 510

Gly Glu Asp Gly Arg Pro Gly Pro Gly Pro Gln Gly Ala Arg Gly  
515 520 525

Gln Pro Gly Val Met Gly Phe Pro Gly Pro Lys Gly Ala Asn Gly Glu  
530 535 540

Pro Gly Lys Ala Gly Glu Lys Gly Leu Pro Gly Ala Pro Gly Leu Arg  
545 550 555 560

Gly Leu Pro Gly Lys Asp Gly Glu Thr Gly Ala Glu Gly Pro Pro Gly  
565 570 575

Pro Ala Gly Pro Ala Gly Glu Arg Gly Glu Gln Gly Ala Pro Gly Pro  
580 585 590

Ser Gly Phe Gln Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Glu Gly  
595 600 605

Gly Lys Pro Gly Asp Gln Gly Val Pro Gly Glu Ala Gly Ala Pro Gly  
610 615 620

Leu Val Gly Pro Arg Gly Glu Arg Gly Phe Pro Gly Glu Arg Gly Ser  
625 630 635 640

Pro Gly Ala Gln Gly Leu Gln Gly Pro Arg Gly Leu Pro Gly Thr Pro  
645 650 655

Gly Thr Asp Gly Pro Lys Gly Ala Ser Gly Pro Ala Gly Pro Pro Gly  
660 665 670

Ala Gln Gly Pro Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Ala  
675 680 685

Ala Gly Ile Ala Gly Pro Lys Gly Asp Arg Gly Asp Val Gly Glu Lys  
690 695 700

Gly Pro Glu Gly Ala Pro Gly Lys Asp Gly Gly Arg Gly Leu Thr Gly  
705 710 715 720

Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala Asn Gly Glu Lys Gly Glu  
725 730 735

Val Gly Pro Pro Gly Pro Ala Gly Ser Ala Gly Ala Arg Gly Ala Pro  
740 745 750

-continued

---

Gly Glu Arg Gly Glu Thr Gly Pro Pro Gly Thr Ser Gly Ile Ala Gly  
           755  760  765

Pro Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Glu Gln Gly Glu  
       770  775  780

Ala Gly Gln Lys Gly Asp Ala Gly Ala Pro Gly Pro Gln Gly Pro Ser  
   785  790  795  800

Gly Ala Pro Gly Pro Gln Gly Pro Thr Gly Val Thr Gly Pro Lys Gly  
   805  810  815

Ala Arg Gly Ala Gln Gly Pro Pro Gly Ala Thr Gly Phe Pro Gly Ala  
   820  825  830

Ala Gly Arg Val Gly Pro Pro Gly Ser Asn Gly Asn Pro Gly Pro Pro  
       835  840  845

Gly Pro Pro Gly Pro Ser Gly Lys Asp Gly Pro Lys Gly Ala Arg Gly  
       850  855  860

Asp Ser Gly Pro Pro Gly Arg Ala Gly Glu Pro Gly Leu Gln Gly Pro  
   865  870  875  880

Ala Gly Pro Pro Gly Glu Lys Gly Glu Pro Gly Asp Asp Gly Pro Ser  
   885  890  895

Gly Ala Glu Gly Pro Pro Gly Pro Gln Gly Leu Ala Gly Gln Arg Gly  
   900  905  910

Ile Val Gly Leu Pro Gly Gln Arg Gly Glu Arg Gly Phe Pro Gly Leu  
       915  920  925

Pro Gly Pro Ser Gly Glu Pro Gly Gln Gln Gly Ala Pro Gly Ala Ser  
       930  935  940

Gly Asp Arg Gly Pro Pro Gly Pro Val Gly Pro Pro Gly Leu Thr Gly  
   945  950  955  960

Pro Ala Gly Glu Pro Gly Arg Glu Gly Ser Pro Gly Ala Asp Gly Pro  
   965  970  975

Pro Gly Arg Asp Gly Ala Ala Gly Val Lys Gly Asp Arg Gly Glu Thr  
   980  985  990

Gly Ala Val Gly Ala Pro Gly Ala Pro Gly Pro Pro Gly Ser Pro Gly  
   995  1000  1005

Pro Ala Gly Pro Thr Gly Lys Gln Gly Asp Arg Gly Glu Ala Gly Ala  
   1010  1015  1020

Gln Gly Pro Met Gly Pro Ser Gly Pro Ala Gly Ala Arg Gly Ile Gln  
   1025  1030  1035  1040

Gly Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu Ala Gly Glu Pro Gly  
   1045  1050  1055

Glu Arg Gly Leu Lys Gly His Arg Gly Phe Thr Gly Leu Gln Gly Leu  
   1060  1065  1070

Pro Gly Pro Pro Gly Pro Ser Gly Asp Gln Gly Ala Ser Gly Pro Ala  
       1075  1080  1085

Gly Pro Ser Gly Pro Arg Gly Pro Pro Gly Pro Val Gly Pro Ser Gly  
       1090  1095  1100

Lys Asp Gly Ala Asn Gly Ile Pro Gly Pro Ile Gly Pro Pro Gly Pro  
   1105  1110  1115  1120

Arg Gly Arg Ser Gly Glu Thr Gly Pro Ala Gly Pro Pro Gly Asn Pro  
   1125  1130  1135

Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Gly Ile Asp Met Ser  
   1140  1145  1150

Ala Phe Ala Gly Leu Gly Pro Arg Glu Lys Gly Pro Asp Pro Leu Gln

-continued

1155					1160					1165					
Tyr	Met	Arg	Ala	Asp	Gln	Ala	Ala	Gly	Gly	Leu	Arg	Gln	His	Asp	Ala
	1170					1175					1180				
Glu	Val	Asp	Ala	Thr	Leu	Lys	Ser	Leu	Asn	Asn	Gln	Ile	Glu	Ser	Ile
	1185					1190					1195				1200
Arg	Ser	Pro	Glu	Gly	Ser	Arg	Lys	Asn	Pro	Ala	Arg	Thr	Cys	Arg	Asp
				1205					1210					1215	
Leu	Lys	Leu	Cys	His	Pro	Glu	Trp	Lys	Ser	Gly	Asp	Tyr	Trp	Ile	Asp
			1220						1225					1230	
Pro	Asn	Gln	Gly	Cys	Thr	Leu	Asp	Ala	Met	Lys	Val	Phe	Cys	Asn	Met
		1235						1240					1245		
Glu	Thr	Gly	Glu	Thr	Cys	Val	Tyr	Pro	Asn	Pro	Ala	Asn	Val	Pro	Lys
	1250						1255					1260			
Lys	Asn	Trp	Trp	Ser	Ser	Lys	Ser	Lys	Glu	Lys	Lys	His	Ile	Trp	Phe
	1265					1270					1275				1280
Gly	Glu	Thr	Ile	Asn	Gly	Gly	Phe	His	Phe	Ser	Tyr	Gly	Asp	Asp	Asn
				1285					1290					1295	
Leu	Ala	Pro	Asn	Thr	Ala	Asn	Val	Gln	Met	Thr	Phe	Leu	Arg	Leu	Leu
			1300					1305						1310	
Ser	Thr	Glu	Gly	Ser	Gln	Asn	Ile	Thr	Tyr	His	Cys	Lys	Asn	Ser	Ile
		1315					1320					1325			
Ala	Tyr	Leu	Asp	Glu	Ala	Ala	Gly	Asn	Leu	Lys	Lys	Ala	Leu	Leu	Ile
	1330						1335					1340			
Gln	Gly	Ser	Asn	Asp	Val	Glu	Ile	Arg	Ala	Glu	Gly	Asn	Ser	Arg	Phe
	1345						1350					1355			1360
Thr	Tyr	Thr	Ala	Leu	Lys	Asp	Gly	Cys	Thr	Lys	His	Thr	Gly	Lys	Trp
				1365					1370					1375	
Gly	Lys	Thr	Val	Ile	Glu	Tyr	Arg	Ser	Gln	Lys	Thr	Ser	Arg	Leu	Pro
			1380						1385					1390	
Ile	Ile	Asp	Ile	Ala	Pro	Met	Asp	Ile	Gly	Gly	Pro	Glu	Gln	Glu	Phe
		1395					1400					1405			
Gly	Val	Asp	Ile	Gly	Pro	Val	Cys	Phe	Leu						
	1410						1415								

## (2) INFORMATION FOR SEQ ID NO: 21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1078 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: COLLAGEN ALPHA 1 (III)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Gln	Asn	Tyr	Ser	Pro	Gln	Tyr	Asp	Ser	Tyr	Asp	Val	Lys	Ser	Gly	Gly
1				5					10					15	
Val	Ala	Val	Gly	Gly	Leu	Ala	Gly	Tyr	Pro	Gly	Pro	Ala	Gly	Pro	Pro
			20					25					30		
Gly	Pro	Pro	Gly	Pro	Pro	Gly	Thr	Ser	Gly	His	Pro	Gly	Ser	Pro	Gly
		35					40						45		

-continued

---

Ser Pro Gly Tyr Gln Gly Pro Pro Gly Glu Pro Gly Gln Ala Gly Pro  
 50 55 60

Ser Gly Pro Pro Gly Pro Gly Ala Ile Gly Pro Ser Gly Pro Ala  
 65 70 75 80

Gly Lys Asp Gly Glu Ser Gly Arg Pro Gly Arg Pro Gly Asp Arg Gly  
 85 90 95

Leu Pro Gly Pro Pro Gly Ile Lys Gly Pro Ala Gly Ile Pro Gly Phe  
 100 105 110

Pro Gly Met Lys Gly His Arg Gly Phe Asp Gly Arg Asn Gly Glu Lys  
 115 120 125

Gly Glu Thr Gly Ala Pro Gly Leu Lys Gly Glu Asn Gly Leu Pro Gly  
 130 135 140

Glu Asn Gly Ala Pro Gly Pro Met Gly Pro Arg Gly Ala Pro Gly Glu  
 145 150 155 160

Arg Gly Arg Pro Gly Leu Pro Gly Ala Ala Gly Ala Arg Gly Asn Asp  
 165 170 175

Gly Ala Arg Gly Ser Asp Gly Gln Pro Gly Pro Pro Gly Pro Pro Gly  
 180 185 190

Thr Ala Gly Phe Pro Gly Ser Pro Gly Ala Lys Gly Glu Val Gly Pro  
 195 200 205

Ala Gly Ser Pro Gly Ser Asn Gly Ala Pro Gly Gln Arg Gly Glu Pro  
 210 215 220

Gly Pro Gln Gly His Ala Gly Ala Gln Gly Pro Pro Gly Pro Pro Gly  
 225 230 235 240

Ile Asn Gly Ser Pro Gly Gly Lys Gly Glu Met Gly Pro Ala Gly Ile  
 245 250 255

Pro Gly Ala Pro Gly Leu Met Gly Ala Arg Gly Pro Pro Gly Pro Ala  
 260 265 270

Gly Ala Asn Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly Glu Pro Gly  
 275 280 285

Lys Asn Gly Ala Lys Gly Glu Pro Gly Pro Arg Gly Glu Arg Gly Glu  
 290 295 300

Ala Gly Ile Pro Gly Val Pro Gly Ala Lys Gly Glu Asp Gly Lys Asp  
 305 310 315 320

Gly Ser Pro Gly Asp Pro Gly Ala Asn Gly Leu Pro Gly Ala Ala Gly  
 325 330 335

Glu Arg Gly Ala Leu Gly Ser Arg Gly Pro Ala Gly Pro Asn Gly Ile  
 340 345 350

Pro Gly Glu Lys Gly Pro Ala Gly Glu Arg Gly Ala Pro Gly Pro Ala  
 355 360 365

Gly Pro Arg Gly Ala Ala Gly Glu Pro Gly Arg Asp Gly Val Pro Gly  
 370 375 380

Gly Pro Gly Met Arg Gly Met Pro Gly Ser Pro Gly Gly Pro Gly Ser  
 385 390 395 400

Asp Gly Lys Pro Gly Pro Pro Gly Ser Gln Gly Glu Ser Gly Arg Pro  
 405 410 415

Gly Pro Pro Gly Pro Ser Gly Pro Arg Gly Gln Pro Gly Val Met Gly  
 420 425 430

Phe Pro Gly Pro Lys Gly Asn Asp Gly Ala Pro Gly Lys Asn Gly Glu  
 435 440 445

-continued

---

Arg Gly Gly Pro Gly Gly Pro Gly Pro Gln Gly Pro Pro Gly Lys Asn  
 450 455 460

Gly Glu Tyr Gly Pro Gln Gly Pro Pro Gly Pro Thr Gly Pro Gly Gly  
 465 470 475 480

Asp Lys Gly Asp Thr Gly Pro Arg Gly Pro Gln Gly Leu Gln Gly Leu  
 485 490 495

Pro Gly Thr Gly Gly Pro Pro Gly Glu Asn Glu Lys Pro Gly Glu Pro  
 500 505 510

Gly Pro Lys Gly Glu Ala Gly Ala Pro Gly Ala Pro Gly Gly Lys Gly  
 515 520 525

Asp Ala Gly Ala Pro Gly Glu Arg Gly Pro Pro Gly Leu Ala Gly Ala  
 530 535 540

Pro Gly Leu Arg Gly Gly Ala Gly Pro Pro Gly Pro Glu Gly Gly Lys  
 545 550 555 560

Gly Ala Ala Gly Pro Pro Gly Pro Pro Gly Ala Ala Gly Thr Pro Gly  
 565 570 575

Leu Gln Gly Met Pro Gly Glu Arg Gly Gly Leu Gly Ser Pro Gly Pro  
 580 585 590

Lys Gly Asp Lys Gly Glu Pro Gly Gly Pro Gly Ala Asp Gly Val Pro  
 595 600 605

Gly Lys Asp Gly Pro Arg Gly Pro Thr Gly Pro Ile Gly Pro Pro Gly  
 610 615 620

Pro Ala Gly Gln Pro Gly Asp Lys Gly Glu Gly Gly Ala Pro Gly Leu  
 625 630 635 640

Pro Gly Ile Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Thr  
 645 650 655

Gly Pro Pro Gly Pro Ala Gly Phe Pro Gly Ala Pro Gly Gln Asn Gly  
 660 665 670

Glu Pro Gly Gly Lys Gly Glu Arg Gly Ala Pro Gly Glu Lys Gly Glu  
 675 680 685

Gly Gly Pro Pro Gly Val Ala Val Pro Pro Gly Gly Ser Gly Pro Ala  
 690 695 700

Gly Pro Pro Gly Pro Gln Gly Val Lys Gly Glu Arg Gly Ser Pro Gly  
 705 710 715 720

Gly Pro Gly Ala Ala Gly Phe Pro Gly Ala Arg Gly Leu Pro Gly Pro  
 725 730 735

Pro Gly Ser Asn Gly Asn Pro Gly Pro Pro Gly Pro Ser Gly Ser Pro  
 740 745 750

Gly Lys Asp Gly Pro Pro Gly Pro Ala Gly Asn Thr Gly Ala Pro Gly  
 755 760 765

Ser Pro Gly Val Ser Gly Pro Lys Gly Asp Ala Gly Gln Pro Gly Glu  
 770 775 780

Lys Gly Ser Pro Gly Ala Gln Gly Pro Pro Gly Ala Pro Gly Pro Leu  
 785 790 795 800

Gly Ile Ala Gly Ile Thr Gly Ala Arg Gly Leu Ala Gly Pro Pro Gly  
 805 810 815

Met Pro Gly Pro Arg Gly Ser Pro Gly Pro Gln Gly Val Lys Gly Glu  
 820 825 830

Ser Gly Lys Pro Gly Ala Asn Gly Leu Ser Gly Glu Arg Gly Pro Pro  
 835 840 845

Gly Pro Gln Gly Leu Pro Gly Leu Ala Gly Thr Ala Gly Glu Pro Gly

-continued

850	855	860
Arg Asp Gly Asn Pro Gly Ser Asp Gly Leu Pro Gly Arg Asp Gly Ser 865 870 875 880		
Pro Gly Gly Lys Gly Asp Arg Gly Glu Asn Gly Ser Pro Gly Ala Pro 885 890 895		
Gly Ala Pro Gly His Pro Gly Pro Pro Gly Pro Val Gly Pro Ala Gly 900 905 910		
Lys Ser Gly Asp Arg Gly Glu Ser Gly Pro Ala Gly Pro Ala Gly Ala 915 920 925		
Pro Gly Pro Ala Gly Ser Arg Gly Ala Pro Gly Pro Gln Gly Pro Arg 930 935 940		
Gly Asp Lys Gly Glu Thr Gly Glu Arg Gly Ala Ala Gly Ile Lys Gly 945 950 955 960		
His Arg Gly Phe Pro Gly Asn Pro Gly Ala Pro Gly Ser Pro Gly Pro 965 970 975		
Ala Gly Gln Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala Gly Pro Arg 980 985 990		
Gly Pro Val Gly Pro Ser Gly Pro Pro Gly Lys Asp Gly Thr Ser Gly 995 1000 1005		
His Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg Gly Asn Arg Gly Glu 1010 1015 1020		
Arg Gly Ser Glu Gly Ser Pro Gly His Pro Gly Gln Ser Gly Pro Pro 1025 1030 1035 1040		
Gly Pro Pro Gly Ala Pro Gly Pro Cys Cys Gly Gly Val Gly Ala Pro 1045 1050 1055		
Ala Ile Ala Gly Ile Gly Ala Glu Lys Ala Gly Gly Phe Ala Pro Tyr 1060 1065 1070		
Tyr Gly Asp Glu Pro Met 1075		

What is claimed is:

1. A method of determining collagen fragments in a body fluid, wherein a sample of said body fluid is brought into contact with at least one immunological binding partner for the collagen fragments, said binding partner being an antibody immunoreactive with synthetic peptides the sequences of which are essentially derived from collagen and containing potential sites for cross-linking, said immunological binding partners being incorporated, either as whole antibodies or as immunologically active fragments thereof, in an assay for quantitative determination of collagen fragments in the sample.

2. A method according to claim 1, wherein the sample of body fluid in addition to the contacting with the immunological binding partner(s) is brought into direct contact with the corresponding synthetic peptide containing potential sites for cross-linking.

3. A method according to claim 1, wherein the immunological binding partner has been raised by immunization with the corresponding synthetic peptide containing potential sites for cross-linking.

4. A method according to claim 2, wherein the immunological binding partner has been raised by immunization with the corresponding synthetic peptide containing potential sites for cross-linking.

5. A method according to claim 1, wherein the potential sites for cross-linking comprise lysine or hydroxylysine residues incorporated in the peptide sequence.

6. A method according to claim 1, wherein the sequence of the synthetic peptide is derived from the sequence of human collagen type I and consisting essentially of one of the following structures

Asp-Glu-Lys-Ser-Thr-Gly-Gly  
Glu-Lys-Ala-His-Asp-Gly-Gly-Arg  
Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly  
Gly-Met-Lys-Gly-His-Arg  
Gly-Ile-Lys-Gly-His-Arg  
Gly-Phe-Lys-Gly-Ile-Arg

or Gly-Leu-Pro-Gly-Leu-Lys-Gly-His-Asn.

7. A method according to claim 2, wherein the sequence of the synthetic peptide is derived from the sequence of human collagen type I and consisting essentially of one of the following structures

Asp-Glu-Lys-Ser-Thr-Gly-Gly  
Glu-Lys-Ala-His-Asp-Gly-Gly-Arg

Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly

Gly-Met-Lys-Gly-His-Arg

Gly-Ile-Lys-Gly-His-Arg

Gly-Phe-Lys-Gly-Ile-Arg

or Gly-Leu-Pro-Gly-Leu-Lys-Gly-His-Asn.

**8.** A method according to claim 1, wherein the sequence of the synthetic peptide is derived from the sequence of human collagen type II and consisting essentially of one of the following structures

Glu-Lys-Gly-Pro-Asp

Gly-Val-Lys

Pro-Gly-Val-Lys-Gly

Pro-Gly-Pro-Lys-Gly-Glu

Gly-Gln-Lys-Gly-Glu-Pro

or Gly-Asp-Ile-Lys-Asp-Ile-Val.

**9.** A method according to claim 2, wherein the sequence of the synthetic peptide is derived from the sequence of human collagen type II and consisting essentially of one of the following structures

Glu-Lys-Gly-Pro-Asp

Gly-Val-Lys

Pro-Gly-Val-Lys-Gly

Pro-Gly-Pro-Lys-Gly-Glu

Gly-Gln-Lys-Gly-Glu-Pro

or Gly-Asp-Ile-Lys-Asp-Ile-Val.

**10.** A method according to claim 1, wherein the sequence of the synthetic peptide is derived from the sequence of human collagen type III and consisting essentially of one of the following structures:

Asp-Val-Lys-Ser-Gly-Val

Glu-Lys-Ala-Gly-Gly-Phe-Ala

Gly-Phe-Pro-Gly-Met-Lys-Gly-His-Arg

or Gly-Ala-Ala-Gly-Ile-Lys-Gly-His-Arg.

**11.** A method according to claim 2, wherein the sequence of the synthetic peptide is derived from the sequence of human collagen type III and consisting essentially of one of the following structures:

Asp-Val-Lys-Ser-Gly-Val

Glu-Lys-Ala-Gly-Gly-Phe-Ala

Gly-Phe-Pro-Gly-Met-Lys-Gly-His-Arg

or Gly-Ala-Ala-Gly-Ile-Lys-Gly-His-Arg.

**12.** A method according to claim 1, wherein the body fluid is human urine, blood, serum or synovial fluid.

**13.** A cell line that produces a monoclonal antibody binding to any of the synthetic peptides used in the method according to claim 1.

**14.** A cell line that produces a monoclonal antibody binding to any of the synthetic peptides used in the method according to claim 2.

**15.** A monoclonal antibody produced by the cell line according to claim 13.

**16.** An immunological binding partner raised by immunization with synthetic peptides selected from the group consisting of sequences derived from the sequence of human collagen type I and consisting essentially of one of the following structures

Asp-Glu-Lys-Ser-Thr-Gly-Gly

Glu-Lys-Ala-His-Asp-Gly-Gly-Arg

Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly

Gly-Met-Lys-Gly-His-Arg

Gly-Ile-Lys-Gly-His-Arg

Gly-Phe-Lys-Gly-Ile-Arg

and Gly-Leu-Pro-Gly-Leu-Lys-Gly-His-Asn,

sequences derived from the sequence of human collagen type II and consisting essentially of one of the following structures

Glu-Lys-Gly-Pro-Asp

Gly-Val-Lys

Pro-Gly-Val-Lys-Gly

Pro-Gly-Pro-Lys-Gly-Glu

Gly-Gln-Lys-Gly-Glu-Pro

and Gly-Asp-Ile-Lys-Asp-Ile-Val, and

sequences derived from the sequence of human collagen type III and consisting essentially of one of the following structures:

Asp-Val-Lys-Ser-Gly-Val

Glu-Lys-Ala-Gly-Gly-Phe-Ala

Gly-Phe-Pro-Gly-Met-Lys-Gly-His-Arg

and Gly-Ala-Ala-Gly-Ile-Lys-Gly-His-Arg,

and said polyclonal antibody being used for the preparation of an immunological binding partner.

**17.** A test kit for quantitating the amount of collagen fragments in a body fluid, said kit comprising at least one immunological binding partner immunoreactive with a synthetic peptide having a sequence essentially derived from collagen and containing one or more potential sites for cross-linking.

**18.** A method of diagnosing the presence of disorders associated with the metabolism of collagen in a patient, said method comprising the steps of:

(a) contacting a sample of body fluid collected from said patient with at least one immunological binding partner for collagen fragments, said binding partner being an antibody or a fragment thereof which is immunoreactive with synthetic peptides the sequences of which are essentially derived from collagen and containing potential sites for cross-linking,

(b) detecting the quantity of said antibody bound to collagen fragments in the sample, and

(c) comparing said quantity to a previously established standard based on binding of said antibody in samples originating from control subjects not suffering from any disorder associated with the metabolism of collagen.

**19.** A method according to claim 18, wherein the antibody has been raised by immunization with the corresponding synthetic peptide containing potential sites for cross-linking.

**20.** The method according to claim 18, which includes combining the determination of collagen fragments with other markers of the metabolism of bone tissue, connective tissue and other tissues in order to diagnose a given disorder.

**21.** A method for determining whether a susceptible subject is suffering from collagen degradation comprising the steps of:

- (a) contacting a sample of body fluid collected from said subject with an antibody that is specifically immunochemically reactive with an antigenic determinant of said collagen, said antigenic determinant consisting essentially of (i) a potentially crosslinkable site of the molecule of said collagen or (ii) an antigenic determinant essentially immediately adjacent to a potentially crosslinkable site on said collagen molecule;
- (b) detecting the quantity of said antibody bound to collagen fragments in said sample; and

(c) comparing said quantity to a previously established standard based on binding of said antibody in samples from control subjects not suffering from collagen degradation.

**22.** A method for determining the presence of collagen degradation products in a body fluid comprising the steps of:

- (a) contacting a sample of said body fluid with an antibody that is specifically immunochemically reactive with an antigenic determinant of said collagen, said antigenic determinant consisting essentially of (i) a potentially crosslinkable site of the molecule of said collagen or (ii) an antigenic determinant essentially immediately adjacent to a potentially crosslinkable site on said collagen molecule; and
- (b) detecting the quantity of said antibody bound to collagen fragments in said sample.

\* \* \* \* \*